WO2001011054A1 - CRYSTALLIZATION AND STRUCTURE DETERMINATION OF STAPHYLOCOCCUS AUREUS UDP-N-ACETYLENOLPYRUVYLGLUCOSAMINE REDUCTASE (S. AUREUS MurB) - Google Patents

CRYSTALLIZATION AND STRUCTURE DETERMINATION OF STAPHYLOCOCCUS AUREUS UDP-N-ACETYLENOLPYRUVYLGLUCOSAMINE REDUCTASE (S. AUREUS MurB) Download PDF

Info

Publication number
WO2001011054A1
WO2001011054A1 PCT/US2000/021432 US0021432W WO0111054A1 WO 2001011054 A1 WO2001011054 A1 WO 2001011054A1 US 0021432 W US0021432 W US 0021432W WO 0111054 A1 WO0111054 A1 WO 0111054A1
Authority
WO
WIPO (PCT)
Prior art keywords
molecule
murb
molecular complex
binding pocket
aureus
Prior art date
Application number
PCT/US2000/021432
Other languages
French (fr)
Other versions
WO2001011054A9 (en
Inventor
Timothy E. Benson
Melissa S. Harris
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Priority to JP2001515839A priority Critical patent/JP2003523175A/en
Priority to EP00952557A priority patent/EP1200599A1/en
Priority to AU65231/00A priority patent/AU782516B2/en
Priority to CA002378032A priority patent/CA2378032A1/en
Publication of WO2001011054A1 publication Critical patent/WO2001011054A1/en
Publication of WO2001011054A9 publication Critical patent/WO2001011054A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Definitions

  • This invention relates to the crystallization and structure determination of Staphylococcus aureus UDP-N-acetylenolpyravylglucosamine reductase (S. aureus MurB).
  • Bacterial peptidoglycan is a polymer which includes a repeating disaccharide subunit of N-acetylglucosamine and N-acetylmuramic acid and an extended four to five residue amino acid chain.
  • the first step toward creating this peptidoglycan polymer involves the formation of UDP-N-acetylmuramic acid from UDP-N-acetylglucosamine by the enzymes MurA and MurB.
  • MurA catalyzes the first stage of this transformation by transferring the enolpyruvate moiety of phosphoenolpyruvate to the 3' hydroxyl of UDP-N-acetylglucosamine with the release of inorganic phosphate.
  • This two electron reduction creates the lactyl ether of UDP- N- acetylmuramic acid upon which a five residue peptide chain is built.
  • Construction of this pentapeptide is catalyzed in a nonribosomal fashion by the enzymes MurC, MurD, MurE, and MurF ( Figure 1) in both Gram negative bacteria such as Escherichia coli and Gram positive bacteria such as Staphylococcus aureus.
  • UDP- N-acetylmuramyl pentapeptide is subsequently attached to an undecaprenyl lipid moiety by MraY and joined to another sugar, UDP-N-acetylglucosamine by MurG.
  • the next steps of peptidoglycan biosynthesis involve another family of enzymes, FemX, FemA, and FemB which create a pentaglycine strand in a stepwise fashion on the amino terminus of the lysine side chain. This extended Lys-Gly 5 chain serves as the interstrand bridge between nearby peptide strands.
  • Crosslinking between strands can then occur between the lysine-pentapeptide bridge and the carbonyl of the fourth residue (D-Ala) with release of the terminal D-Ala in a transpeptidation step catalyzed by penicillin binding proteins.
  • the present invention provides a method for crystallizing an S. aureus MurB molecule or molecular complex that includes preparing purified S. aureus MurB at a concentration of about 1 mg/ml to about 50 mg/ml and crystallizing S. aureus MurB from a solution comprising about 1 wt. % to about 50 wt. % PEG, 0 wt. % to about 40 wt.
  • the present invention provides crystalline forms of an S. aureus MurB molecule.
  • a crystal of an S. aureus MurB is provided having the trigonal space group symmetry 12 ⁇ .
  • the present invention provides a scalable three dimensional configuration of points derived from structure coordinates of at least a portion of an S. aureus MurB molecule or molecular complex.
  • the scalable three dimensional set of points is derived from structure coordinates of at least the backbone atoms of the amino acids representing a FAD and or substrate binding pocket of an S. aureus MurB molecule or molecular complex.
  • the scalable three dimensional set of points is derived from structure coordinates of at least a portion of a molecule or a molecular complex that is structurally homologous to an S. aureus MurB molecule or molecular complex.
  • the configuration of points derived from a homologous molecule or molecular complex have a root mean square deviation of less than about 1.0 A from the structure coordinates of the molecule or complex
  • the present invention provides a molecule or molecular complex that includes at least a portion of an S. aureus MurB FAD and/or substrate binding pocket.
  • the S. aureus MurB FAD binding pocket includes the amino acids listed in Table 1, preferably the amino acids listed in Table 2, and more preferably the amino acids listed in Table 3, the FAD binding pocket being defined by a set of points having a root mean square deviation of less than about 1.7 A, preferably less than about 1.0 A, from points representing the backbone atoms of the amino acids.
  • the S. aureus MurB FAD binding pocket includes the amino acids listed in Table 1, preferably the amino acids listed in Table 2, and more preferably the amino acids listed in Table 3, the FAD binding pocket being defined by a set of points having a root mean square deviation of less than about 1.7 A, preferably less than about 1.0 A, from points representing the backbone atoms of the amino acids.
  • the S. aureus MurB FAD binding pocket includes the amino acids listed in Table 1, preferably the amino acids listed in Table
  • aureus MurB substrate binding pocket includes the amino acids listed in Table 4, preferably the amino acids listed in Table 5, and more preferably the amino acids listed in Table 6, the substrate binding pocket being defined by a set of points having a root mean square deviation of less than about 1.0 A from points representing the backbone atoms of the amino acids.
  • the present invention provides molecules or molecular complexes that are structurally homologous to an S. aureus MurB molecule or molecular complex.
  • the present invention provides a machine readable storage medium including the structure coordinates of all or a portion of an S. aureus MurB molecule, molecular complex, a structurally homologous molecule or complex, including structurally equivalent structures, as defined herein, particularly an FAD or substrate binding pocket thereof, or a similarly shaped homologous binding pocket.
  • a storage medium encoded with these data is capable of displaying on a computer screen, or similar viewing device, a three-dimensional graphical representation of a molecule or molecular complex which comprises a binding pocket or a similarly shaped homologous binding pocket.
  • the present invention provides a method for identifying inhibitors, ligands, and the like of an S. aureus MurB molecule by providing the coordinates of a molecule of S. aureus MurB to a computerized modeling system; identifying chemical entities that are likely to bind to or interfere with the molecule (e.g., screening a small molecule library); and, optionally, procuring or synthesizing and assaying the compounds or analogues derived therefrom for bioactivity.
  • the present invention provides methods for designing inhibitors, ligands, and the like by providing the coordinates of a molecule of S.
  • aureus MurB to a computerized modeling system; designing a chemical entity that is likely to bind to or interfere with the molecule; and, optionally, synthesizing the chemical entity and assaying the chemical entity for bioactivity.
  • the present invention provides inhibitors and ligands designed by the above method.
  • a composition is provided that includes an inhibitor or ligand designed or identified by the above method.
  • the composition is a pharmaceutical composition.
  • the present invention provides a method involving molecular replacement to obtain structural information about a molecule or molecular complex of unknown structure.
  • the method includes crystallizing the molecule or molecular complex, generating an x-ray diffraction pattern from the crystallized molecule or molecular complex, and applying at least a portion of the structure coordinates set forth in Figure 4 to the x-ray diffraction pattern to generate a three-dimensional electron density map of at least a portion of the molecule or molecular complex.
  • the present invention provides a method for homology modeling an S. aureus MurB homolog.
  • F ⁇ F I is less than about 35% for the reflections between 8 A and 4 A.
  • Uridine diphospho-N-acetylglucosamine (UDPGlc ⁇ Ac).
  • Uridine diphospho-N-acetylglucosamine enolpyruvate (EP-UDPGlc ⁇ Ac).
  • Uridine diphospho-N-acetylmuramic acid (UDPMur ⁇ Ac).
  • DTT Dithiothreitol
  • Flavin adenine dinucleotide FAD
  • DMSO Dimethyl sulfoxide
  • Arg Arginine
  • Figure 1 shows the pathway for the biosynthesis of the UDP-N- acetylmuramyl pentapeptide, detailing the first two steps catalyzed by the enzymes MurA and MurB.
  • Figure 2 shows an amino acid sequence alignment for recombinant S. aureus (SEQ ID ⁇ O:l, which includes the His 6 region) and E. coli MurB. Dots in the sequences indicate gaps inserted in order to optimize the alignment. Identical residues are indicate by
  • GAP GAP
  • Figure 3 shows a) solvent flattened MAD electron density map at 2.3 A resolution for residues 110-115 with the final model and b) final 2F 0 -F C electron density map at 2.3 A for residues 110-115 with the final model.
  • Figure 4 lists the atomic structure coordinates for molecule S. aureus MurB as derived by x-ray diffraction from a crystal of that complex. The following abbreviations are used in Figure 4:
  • Atom refers to the element whose coordinates are measured.
  • the second column defines the number of the atom in the structure.
  • the letters in the third column define the element.
  • the fourth and fifth columns define the amino acid and the number of the amino acid in the structure, respectively.
  • Occ is an occupancy factor that refers to the fraction of the molecules in which each atom occupies the position specified by the coordinates. A value of "1" indicates that each atom has the same conformation, i.e., the same position, in all molecules of the crystal.
  • B is a thermal factor that measures movement of the atom around its atomic center.
  • Figure 5 shows ribbon diagrams of a) S. aureus MurB structure with bound FAD cofactor and b) E. coli MurB structure with bound FAD cofactor and ⁇ P-UDPGlcNAc substrate.
  • Figure 6 shows secondary structure diagram for a) S. aureus MurB and b) E. coli MurB.
  • the domain assignments are indicated with a dotted line. Naming of the secondary structure was made to correspond to the previously published E. coli MurB structure. Where new elements of secondary structure are present in the S. aureus structure, naming includes an "A.”
  • Figure 7 shows the superposition of S. aureus MurB (thick lines) and E. coli MurB (thin lines). Residues used for superpositions of the various domains are: a) All C ⁇ atoms in common between the two structures, b) C ⁇ atoms in domain 1 (lower right of molecule as shown in part a). The arrow points to the additional N-terminal ⁇ helix and ⁇ strand present in the S. aureus MurB structure, c) C ⁇ atoms in domain 2 (upper center of molecule as shown in part a). The arrow points to the Tyr 190 loop in the E. coli MurB structure which is absent in the S.
  • FIG. 8 shows a schematic view of side chain and main chain interactions between S. aureus MurB and the FAD cofactor. Residues for the S. aureus enzyme ("SA" prefix) are indicated adjacent to the amino acid along with the corresponding residues for the E. coli enzyme ("EC" prefix). Distances which would allow hydrogen bonds with the FAD are shown as dotted lines.
  • Figure 9 shows proposed binding interactions of S. aureus
  • Figure 10 shows the sequence alignment of a representative sample of MurB sequences from Genbank: MURB HELPY (Helicobacter pylori), MURB_AQUAE (Aquifex aeolicus), MURB_BACSU (Bacillus subtilis), MURB_BORBU (Borrelia burgdorfer ⁇ ), MURB CHLPN (Chlamydia pneumoniae), MURB_RICPR (Rickettsia prowazekii), MURB_SAURE (Staphylococcus aureus), MURB_ECOLI (Escherichia coli), MURB_HAEIN (Haemophilus influenzae), MURB SALTY (Salmonella typhimurium), and
  • MURB BORDE Bacilla pertussis
  • Asterisks indicate the proposed active site residues involved in catalysis.
  • Several other MurB sequences were not included in this alignment including Treponema pallidum MurB (class II MurB) and Mycobacterium tuberculosis MurB (class I MurB) because of additional insertions or deletions in these protein sequences which complicated the multiple sequence alignment.
  • Figure 11 shows C ⁇ backbone traces from three MurB structures (superposition based on the flavin binding domains). The two E. coli MurB structures (substrate free E.
  • EP-UDPGlcNAc bound MurB shown as thin lines show that the substrate binding domain is actually closer to the flavin binding domain in the absence of substrate than when the substrate is bound.
  • the S. aureus MurB structure reveals the greatest displacement of the substrate binding domain from the flavin domain of the three structures.
  • Figure 12 lists the structure factors and multiple anomalous dispersion phases for the crystal structure of S. aureus MurB.
  • INDE refers to the indices h, k, and 1 (columns 2, 3, and 4 respectively) of the lattice planes.
  • FOBS refers to the structure factor of the observed reflections.
  • SIGMA is the standard deviation for the observations.
  • PHAS refers to the phase used for the observations.
  • FOM refers to the figure of merit.
  • crystals comprising S. aureus MurB that are suitable for x-ray crystallographic analysis.
  • the three-dimensional structure of S. aureus MurB was solved using high resolution x-ray crystallography.
  • the crystal has the cubic space group Yl ⁇ i.
  • the crystallized enzyme has one molecule in the asymmetric unit and includes a bound FAD cofactor.
  • Purified S. aureus MurB may be crystallized, for example, using the sitting or hanging drop procedure from a solution including about 1 wt. % to about 50 wt. % polyethylene glycol (PEG, preferably having a number average molecular weight between about 200 and about 20,000), 0 to about 40 wt. % DMSO, about 100 mM to about 1 M ammonium or lithium sulfate, about 0 mM to about 20 mM 2-mercaptoethanol, about 0.005 mM to about 40 mM EP-UDPGlcNAc substrate, and buffered to a pH of about 5 to about 8.
  • PEG polyethylene glycol
  • DMSO polyethylene glycol
  • DMSO polyethylene glycol
  • 100 mM to about 1 M ammonium or lithium sulfate about 0 mM to about 20 mM 2-mercaptoethanol
  • about 0.005 mM to about 40 mM EP-UDPGlcNAc substrate and buffere
  • one embodiment of the invention provides an S. aureus MurB or S. aureus MurB/ligand crystal.
  • aureus selenomethionine MurB was prepared by inhibiting endogenous methionine biosynthesis while supplementing the expressing cells with selenomethionine (G.D. Van Duyne et al., J. Mol. Biol. 229, 105-24 (1993); T.E. Benson et al., Nat. Struct. Biol. 2, 644-53 (1995)).
  • Methionine biosynthesis down regulation eliminates the need for transferring the protein expression vector into a met ' strain. This technique reduces the time and effort required for producing selenomethionine inco ⁇ orated protein and results in near quantitative incorporation of selenomethionine into the overexpressed protein.
  • Anomalous and dispersive difference Pattersons revealed the presence of four selenium sites. Solvent-flattened multiple anomalous dispersion phases to 2.3 A revealed an exceptionally clear electron density map with no significant breaks in the main chain. A portion of the electron density map is shown in Figure 3. The structure was refined to 2.3 A resolution with an R-factor of 20.3% and a Free R-factor of 22.3% as described in Tables 7and 8.
  • structure coordinates refers to Cartesian coordinates derived from mathematical equations related to the patterns obtained on diffraction of a monochromatic beam of x-rays by the atoms (scattering centers) of an S. aureus MurB complex in crystal form.
  • the diffraction data are used to calculate an electron density map of the repeating unit of the crystal.
  • the electron density maps are then used to establish the positions of the individual atoms of the S. aureus MurB protein or protein/ligand complex.
  • Slight variations in structure coordinates can be generated by mathematically manipulating the S. aureus MurB or S. aureus MurB/ligand structure coordinates.
  • the structure coordinates set forth in Figure 4 could be manipulated by crystallographic permutations of the structure coordinates, fractionalization of the structure coordinates, integer additions or subtractions to sets of the structure coordinates, inversion of the structure coordinates or any combination of the above.
  • modifications in the crystal structure due to mutations, additions, substitutions, and/or deletions of amino acids, or other changes in any of the components that make up the crystal could also yield variations in structure coordinates.
  • Such slight variations in the individual coordinates will have little effect on overall shape. If such variations are within an acceptable standard error as compared to the original coordinates, the resulting three-dimensional shape is considered to be structurally equivalent. Structural equivalence is described in more detail below.
  • the phrase "associating with” refers to a condition of proximity between a chemical entity, or portions thereof, and an S. aureus thymidylate kinase molecule or portions thereof.
  • the association may be non-covalent, wherein the juxtaposition is energetically favored by hydrogen bonding, van der Waals forces, or electrostatic interactions, or it may be covalent.
  • a ligand that bound to or interfered with the active site binding pocket of S. aureus MurB would also be expected to bind to or interfere with another binding pocket whose structure coordinates define a shape that falls within the acceptable error.
  • S. aureus MurB is composed of three domains ( Figures 5 and 6). Domains 1 and 2 are responsible for binding of the flavin adenine dinucleotide (FAD) cofactor while domain 3 is responsible for substrate binding.
  • the r.m.s. deviation for all C ⁇ atoms in common between the E. coli and S. aureus structures (236 residues out of the 326 S. aureus residues) is 2.20 A (Figure 7a).
  • Superpositions for each of the three domains in S. aureus compared to their respective domains in the E. coli enzyme resulted in slightly better superpositions for domains 2 and 3 ( Figure 7b-d). Domain 1 (residues 14-98) of S.
  • aureus MurB has a r.m.s. deviation of 2.20 A for the C ⁇ atoms compared to E. coli MurB.
  • the second domain of S. aureus MurB (residues 101-229) has a r.m.s. deviation of 1.80 A for the C ⁇ atoms of the corresponding residues in E. coli MurB.
  • S. aureus MurB While the overall fold of the S. aureus MurB enzyme is similar to that of E. coli MurB, several exceptions indicate that the S. aureus MurB structure represents a significant structural variation for the UDP-N- acetylenolpy vylglucosamine reductases. The first major difference is the additional 32 amino acids that are present at the ⁇ -terminus of S. aureus MurB which are not present in the E. coli enzyme. While only 18 of these amino acids are observed in the electron density map (the remaining 14 amino acids are disordered), these residues form an additional ⁇ helix ( ⁇ A) and ⁇ strand ( ⁇ A) at the beginning of the peptide chain. Similar secondary structure elements in S.
  • aureus MurB have been given the corresponding names from E. coli MurB (T. ⁇ . Benson et al., Nat. Struct. Biol. 2, 644-53 (1995)) in order to facilitate the discussion and new elements of secondary structure have been assigned lettered names.
  • the ⁇ A strand adds an antiparallel strand to the central parallel ⁇ barrel which forms the base of domain 1.
  • This ⁇ barrel has an extremely hydrophobic core burying the side chains of residues Leu 37, Leu 78, He 84, He 86, He 91, Val 95, and He 312.
  • S. aureus MurB The second major structural difference in S. aureus MurB is the absence of the loop between ⁇ l3 and ⁇ 3 (residues 183 to 203 of E. coli MurB). To compensate for the loss of this loop, an additional turn of helix is added to ⁇ 3 in order to make the connection between ⁇ l3 and ⁇ 3 in S. aureus MurB.
  • This loop serves an important role in E. coli MurB by positioning Tyr 190 to interact directly with the ⁇ phosphate of the ⁇ P-UDPGlcNAc ligand and to close the active site upon substrate binding (T. ⁇ . Benson et al., Structure 4, 47- 54 (1996)). Observations of the S.
  • aureus MurB structure do not reveal any direct substitutes for Tyr 190 suggesting that this specific mechanism for substrate binding observed in E. coli MurB is not utilized in the S. aureus enzyme.
  • the ⁇ phosphate of the ⁇ P-UDPGlcNAc also interacts with the side chain of Lys 217. This residue is conserved in the S. aureus MurB structure as residue Lys 228. Therefore, one would expect that the absence of Tyr 190 would lead to an increased importance for Lys 228 in the formation of a productive enzyme-substrate complex in S. aureus MurB.
  • the third major structural difference is the deletion of a portion of the substrate binding domain in the S. aureus MurB protein structure.
  • the single split ⁇ fold ( ⁇ l4, ⁇ 4, ⁇ l5, ⁇ l6) is absent in the S. aureus MurB structure.
  • This portion of the E. coli structure provides several van der Waals contacts with the ⁇ P-UDPGlcNAc ligand. In the absence of this portion of the substrate binding domain, the ligand binding surface on S. aureus MurB is notably more narrow. Several minor differences in the main chain between the two structures are also observed. First, in the E. coli MurB, two residues in ⁇ 5 and ⁇ 6 are not found in the S. aureus MurB structure resulting in two shorter ⁇ strands for the S. aureus enzyme.
  • aureus structure occurs in the loop between ⁇ 9 and ⁇ lO leading to a shorter connection between these two strands.
  • the last beta strand ( ⁇ 21) and alpha helix ( ⁇ 7) in the E. coli MurB structure are not observed in the S. aureus MurB structure.
  • the exact secondary structure of these residues is unknown since the last nine residues of the C terminus of S. aureus MurB are disordered in the electron density map.
  • the conserved protein fold of MurB in the S. aureus enzyme is particularly pronounced for the flavin binding portion of the molecule (domains 1 and 2 - Figures 7 b,c). Not only is the flavin binding fold conserved, but also the conformation of the flavin adenine dinucleotide ligand is nearly identical between the two structures (r.m.s. deviation for all of the cofactor atoms comparing the S. aureus FAD and the E. coli FAD is 0.30 A ).
  • This FAD binding fold in both MurB structures is a member of a new superfamily of flavin adenine dinucleotide binding proteins (A.G. Murzin, Cur. Op. Struct. Biol. 6, 386-94 (1996)).
  • the other members of this FAD binding protein family for which protein structures have been solved include p -cresol methylhydroxylase from Pseudomonas putida (F.S. Matthews et al., Biochemistry 30, 238-47 (1991)), vanillyl-alcohol oxidase from Penicllium simplicissimum (A. Mattevi et al., Structure 5, 907-20 (1997)), and CO dehydrogenase from Oligotropha carboxidovorans (H. Dobbek et al., Proc. Natl. Acad. Sci USA 96, 8884-89 (1999)).
  • the protein side chain and main chain interactions with the FAD cofactor found in the S. aureus enzyme are mostly similar to those interactions observed in E. coli MurB.
  • the N5 and O4 of the isoalloxazine ring of the flavin adenine dinucleotide interact with the guanidinium moiety of Arg 225 in a manner similar to that observed for Arg 214 in the E. coli MurB structure (Fig. 8).
  • the sequence and positional conservation of this arginine in the structure suggests that it plays a role in the binding of the flavin and stabilization of the reduced cofactor during catalysis.
  • Two other interactions to the isoalloxazine ring (N3 and O2) are maintained by the main chain nitrogen and carbonyl oxygen of Gly 153.
  • Ser 82 is conserved with respect to its counterpart in E. coli MurB (Ser 50), but Ser 143 is three residues away (one turn of ⁇ helix B) from the position corresponding to the E. coli MurB Ser 116. While this places the serine hydroxyl on the opposite site of the phosphate (when compared to the E. coli MurB), the hydrogen bonding interaction is maintained. Finally, two residues make contacts to the 3' hydroxyl of the ribityl sugar, Tyr 149 and Arg 310. The corresponding residues in E. coli MurB for Tyr 149 is He 149 which does not make any hydrogen bonds to the ribityl sugar, but does make hydrophobic interactions with this part of the flavin. The substitution of tyrosine in S. aureus MurB at this position allows for both hydrogen bonding and hydrophobic contacts.
  • the electron density map in the active site of S. aureus MurB reveals regions of disconnected electron density that did not clearly resemble the ⁇ P-UDPGlcNAc substrate despite the presence of the substrate in the crystallization conditions. Therefore, the exact location and interactions between S. aureus MurB and the ⁇ P-UDPGlcNAc and/or NADPH substrate in the active site cannot be determined at this time.
  • Analysis of the packing in the crystal lattice reveals that a symmetry related molecule protrudes into the active site of S. aureus MurB in this crystal. Specifically, two strands of the major beta sheet ( ⁇ 5 and ⁇ 6) are situated at the active site opening. Superimposing the E.
  • the loop between ⁇ 13 and ⁇ 3 in E. coli MurB contains Tyr 190 which undergoes a dramatic motion upon substrate binding.
  • the absence of this loop and its key residue in the S. aureus structure suggests that ligand binding in this bacterial species has adapted to compensate for the loss of Tyr 190.
  • the K m for EP-UDPGlcNAc with S. aureus MurB is 15 ⁇ M (S. Swaney, personal communication) which is of the same magnitude as the K m for EP-UDPGlcNAc with E. coli MurB.
  • This kinetic parameter suggests that the loss of Tyr 190 has little impact on the enzyme's ability to bind substrate. It is also possible that charged residues from other parts ofthe molecule could play a role in ligand binding.
  • the other significant deletion also involves a part ofthe enzyme involved in substrate binding - the single split ⁇ fold ( ⁇ l4, ⁇ 4, ⁇ l5 and ⁇ l6 in E. coli MurB).
  • This portion of protein structure has a less specific purpose in the mechanism of action of MurB, but does serve to provide a surface on which the uridine portion ofthe EP-UDPGlcNAc substrate rests.
  • the active site for MurB is defined by residues which stabilize the intermediate produced when a hydride is transferred from NI to C3 ofthe enolpyruvyl group and facilitate the quenching of this intermediate.
  • S. aureus MurB structure Based on S. aureus MurB structure, a mechanism was proposed for stabilization of this acicarbanionic species by charge neutralization and/or by protonation.
  • Ser 238 corresponds to E. coli MurB Ser 229 which is proposed to serve as a general acid catalyst in conjunction with an active site water (T.E. Benson et al., Biochemistry 36, 806-11 (1997)).
  • the Ser 238 hydroxyl is 6.3A away from NI ofthe FAD cofactor in the S. aureus MurB structure. Since the corresponding serine hydroxyl is similarly positioned (6.1 A from NI ) in the E. coli MurB structure, it appears that S. aureus MurB is well-positioned for reduction ofthe enolpyruvyl group.
  • This classification of two types of MurB consists not only of secondary structural elements that are present or absent, but also of how these structural elements define a mode of substrate binding.
  • a comparison ofthe substrate domain positions between S. aureus MurB and the two forms of E. coli MurB (substrate free and ⁇ P-UDPGlcNAc bound forms) is shown in Figure 11. This superposition reveals that S. aureus MurB's substrate binding domain is notably more displaced from domains 1 and 2 in either ofthe substrate free or the ⁇ P-UDPGlcNAc bound forms of E. coli MurB. While interactions between crystallographically related molecules hold domain 3 in this open conformation, this displacement reveals the flexibility ofthe enzyme to achieve an open conformation ofthe S.
  • Applicants' invention has provided, for the first time, information about the shape and structure ofthe cofactor and substrate binding pockets of S. aureus MurB.
  • Binding pockets are of significant utility in fields such as drug discovery.
  • the association of natural ligands or substrates with the binding pockets of their corresponding receptors or enzymes is the basis of many biological mechanisms of action.
  • many drugs exert their biological effects through association with the binding pockets of receptors and enzymes.
  • Such associations may occur with all or any parts ofthe binding pocket.
  • An understanding of such associations helps lead to the design of drugs having more favorable associations with their target, and thus improved biological effects. Therefore, this information is valuable in designing potential inhibitors of S. aureus MurB-like binding pockets, as discussed in more detail below.
  • a “molecular complex” means a protein in covalent or non- covalent association with a chemical entity or compound.
  • binding pocket or “active site” as used herein, refers to a region of a molecule or molecular complex, that, as a result of its shape, favorably associates with another chemical entity.
  • a binding pocket may include or consist of features such as cavities, surfaces, or interfaces between domains.
  • Chemical entities that may associate with a binding pocket include, but are not limited to, cofactors, substrates, inhibitors, agonists, antagonists, etc.
  • the FAD binding pocket of S. aureus MurB is located on the interface between domains 1 and 2, and preferably includes the amino acids listed in Table 1, more preferably the amino acids listed in Table 2, and most preferably the amino acids listed in Table 3, as represented by the structure coordinates listed in Figure 4. It will be readily apparent to those of skill in the art that the numbering of amino acids in other isoforms of S. aureus MurB may be different than that of recombinant S. aureus MurB expressed in E. coli. Alternatively, the FAD binding pocket of S.
  • aureus MurB includes those amino acids whose backbone atoms are situated within about 4 A, more preferably within about 7 A, most preferably within about 10 A, of one or more constituent atoms of a bound FAD cofactor or analog, as determined from the structure coordinates listed in Figure 4.
  • the FAD binding pocket comprises those amino acids whose backbone atoms are situated within a sphere centered on the coordinates representing the alpha carbon atom of residue Asn 80, the sphere having a radius of about 16 A, preferably about 20 A, and more preferably about 25 A.
  • aureus MurB is located in domain 3, and preferably includes the amino acids listed in Table 4, more preferably the amino acids listed in Table 5, and most preferably the amino acids listed in Table 6, as represented by the stmcture coordinates listed in Figure 4.
  • the substrate binding pocket of S. aureus MurB includes those amino acids whose backbone atoms are situated within about 4 A, more preferably within about 7 A, most preferably within about 10 A, of one or more constituent atoms of a bound substrate or inhibitor, as determined from the structure coordinates listed in Figure 4.
  • the substrate binding pocket comprises those amino acids whose backbone atoms are situated within a sphere centered on the coordinates representing the alpha carbon atom of residue Ser 238, the sphere having a radius of about 12 A, preferably about 20 A, and more preferably about 25 A.
  • amino acid constituents of an S. aureus MurB binding pocket as defined herein, as well as selected constituent atoms thereof, are positioned in three dimensions in accordance with the structure coordinates listed in Figure 4.
  • the stmcture coordinates defining the binding pocket of S. aureus MurB include structure coordinates of all atoms in the constituent amino acids; in another aspect, the stmcture coordinates ofthe binding pocket include stmcture coordinates of just the backbone atoms ofthe constituent atoms.
  • S. aureus MurB-like binding pocket refers to a portion of a molecule or molecular complex whose shape is sufficiently similar to at least a portion of a cofactor or substrate binding pocket of S. aureus MurB as to be expected to bind a structurally related cofactor such as FAD or structurally related substrates such EP-UDPGlcNAc and/or NADPH.
  • a structurally equivalent binding pocket is defined by a root mean square deviation from the stmcture coordinates ofthe backbone atoms ofthe amino acids that make up the binding pockets in S. aureus MurB (as set forth in Figure 4) of at most about 1.5 A. How this calculation is obtained is described below. Accordingly, the invention thus provides molecules or molecular complexes comprising an S. aureus MurB binding pocket or S. aureus MurB- like binding pocket, as defined by the sets of stmcture coordinates described above.
  • X-ray structure coordinates define a unique configuration of points in space.
  • a set of stmcture coordinates for protein or an protein/ligand complex, or a portion thereof define a relative set of points that, in turn, define a configuration in three dimensions.
  • a similar or identical configuration can be defined by an entirely different set of coordinates, provided the distances and angles between coordinates remain essentially the same.
  • a scalable configuration of points can be defined by increasing or decreasing the distances between coordinates by a scalar factor while keeping the angles essentially the same.
  • the present invention thus includes the scalable three- dimensional configuration of points derived from the stmcture coordinates of at least a portion of an S. aureus MurB molecule or molecular complex, as listed in Figure 4, as well as structurally equivalent configurations, as described below.
  • the scalable three-dimensional configuration includes points derived from stmcture coordinates representing the locations of a plurality ofthe amino acids defining an S. aureus MurB binding pocket.
  • the scalable three-dimensional configuration includes points derived from stmcture coordinates representing the locations of the backbone atoms of a plurality of amino acids defining the S. aureus MurB FAD binding pocket, preferably the amino acids listed is Table 1, more preferably the amino acids listed in Table 2, and most preferably the amino acids listed in Table 3; in another embodiment, the three-dimensional configuration includes points derived from stmcture coordinates representing the locations ofthe side chain and the backbone atoms (other than hydrogens) of a plurality ofthe amino acids defining the S. aureus MurB FAD binding pocket, preferably the amino acids listed is Table 1, more preferably the amino acids listed in Table 2, and most preferably the amino acids listed in Table 3.
  • the scalable three-dimensional configuration includes points derived from stmcture coordinates representing the locations ofthe backbone atoms of a plurality of amino acids defining the S. aureus MurB substrate binding pocket, preferably the amino acids listed is Table 4, more preferably the amino acids listed in Table 5, and most preferably the amino acids listed in Table 6; in another embodiment, the three-dimensional configuration includes points derived from stmcture coordinates representing the locations ofthe side chain and the backbone atoms (other than hydrogens) of a plurality ofthe amino acids defining the S. aureus MurB substrate binding pocket, preferably the amino acids listed is Table 4, more preferably the amino acids listed in Table 5, and most preferably the amino acids listed in Table 6.
  • the invention also includes the scalable three- dimensional configuration of points derived from structure coordinates of molecules or molecular complexes that are structurally homologous to S. aureus MurB, as well as structurally equivalent configurations.
  • Structurally homologous molecules or molecular complexes are defined below.
  • structurally homologous molecules can be identified using the stmcture coordinates of S. aureus MurB ( Figure 4) according to a method ofthe invention.
  • the configurations of points in space derived from structure coordinates according to the invention can be visualized as, for example, a holographic image, a stereodiagram, a model or a computer-displayed image, and the invention thus includes such images, diagrams or models.
  • Various computational analyses can be used to determine whether a molecule or the binding pocket portion thereof is "structurally equivalent,” defined in terms of its three-dimensional stmcture, to all or part of S. aureus MurB or its binding pockets.
  • analyses may be carried out in current software applications, such as the Molecular Similarity application of QUANTA (Molecular Simulations Inc., San Diego, CA) version 4.1, and as described in the accompanying User's Guide.
  • the Molecular Similarity application permits comparisons between different stmctures, different conformations ofthe same stmcture, and different parts ofthe same stmcture.
  • Each structure is identified by a name.
  • One structure is identified as the target (i.e., the fixed structure); all remaining stmctures are working stmctures (i.e., moving structures). Since atom equivalency within QUANTA is defined by user input, for the purpose of this invention equivalent atoms are defined as protein backbone atoms (N, C ⁇ , C, and O) for all conserved residues between the two stmctures being compared. A conserved residue is defined as a residue that is structurally or functionally equivalent. Only rigid fitting operations are considered. When a rigid fitting method is used, the working stmcture is translated and rotated to obtain an optimum fit with the target structure.
  • the fitting operation uses an algorithm that computes the optimum translation and rotation to be applied to the moving stmcture, such that the root mean square difference ofthe fit over the specified pairs of equivalent atom is an absolute minimum. This number, given in angstroms, is reported by QUANTA.
  • structurally equivalent to the reference molecule. That is to say, the crystal structures of those portions ofthe two molecules are substantially identical, within acceptable error.
  • Particularly preferred structurally equivalent molecules or molecular complexes are those that are defined by the entire set of structure coordinates listed in Figure 4, ⁇ a root mean square deviation from the conserved backbone atoms of those amino acids of not more than 1.5 A. More preferably, the root mean square deviation is less than about 1.0 A.
  • the term "root mean square deviation” means the square root ofthe arithmetic mean ofthe squares ofthe deviations. It is a way to express the deviation or variation from a trend or object.
  • the "root mean square deviation” defines the variation in the backbone of a protein from the backbone of S. aureus MurB or a binding pocket portion thereof, as defined by the stmcture coordinates of S. aureus MurB described herein.
  • Transformation ofthe stmcture coordinates for all or a portion of S. aureus MurB or the S. aureus MurB/ligand complex or one of its binding pockets, for structurally homologous molecules as defined below, or for the structural equivalents of any of these molecules or molecular complexes as defined above, into three-dimensional graphical representations ofthe molecule or complex can be conveniently achieved through the use of commercially- available software.
  • the invention thus further provides a machine-readable storage medium comprising a data storage material encoded with machine readable data which, when using a machine programmed with instructions for using said data, is capable of displaying a graphical three-dimensional representation of any of the molecule or molecular complexes of this invention that have been described above.
  • the machine-readable data storage medium comprises a data storage material encoded with machine readable data which, when using a machine programmed with instructions for using said data, is capable of displaying a graphical three-dimensional representation of a molecule or molecular complex comprising all or any parts of an S. aureus MurB binding pocket or an S. aureus MurB-like binding pocket, as defined above.
  • the machine-readable data storage medium is capable of displaying a graphical three-dimensional representation of a molecule or molecular complex defined by the structure coordinates of all ofthe amino acids listed in Figure A, ⁇ a root mean square deviation from the backbone atoms of said amino acids of not more than 1.5 A.
  • the machine-readable data storage medium comprises a data storage material encoded with a first set of machine readable data which comprises the Fourier transform ofthe stmcture coordinates set forth in Figure 4, and which, when using a machine programmed with instructions for using said data, can be combined with a second set of machine readable data comprising the x-ray diffraction pattern of a molecule or molecular complex to determine at least a portion ofthe structure coordinates corresponding to the second set of machine readable data.
  • a system for reading a data storage medium may include a computer comprising a central processing unit (“CPU"), a working memory which may be, e.g., RAM (random access memory) or “core” memory, mass storage memory (such as one or more disk drives or CD-ROM drives), one or more display devices (e.g., cathode-ray tube (“CRT”) displays, light emitting diode (“LED”) displays, liquid crystal displays (“LCDs”), elecfroluminescent displays, vacuum fluorescent displays, field emission displays (“FEDs”), plasma displays, projection panels, etc.), one or more user input devices (e.g., keyboards, microphones, mice, touch screens, etc.), one or more input lines, and one or more output lines, all of which are interconnected by a conventional bidirectional system bus.
  • CPU central processing unit
  • working memory which may be, e.g., RAM (random access memory) or “core” memory, mass storage memory (such as one or more disk drives or CD-ROM drives), one or more display
  • the system may be a stand-alone computer, or may be networked (e.g., through local area networks, wide area networks, intranets, extranets, or the internet) to other systems (e.g., computers, hosts, servers, etc.).
  • the system may also include additional computer controlled devices such as consumer electronics and appliances.
  • Input hardware may be coupled to the computer by input lines and may be implemented in a variety of ways. Machine-readable data of this invention may be inputted via the use of a modem or modems connected by a telephone line or dedicated data line. Alternatively or additionally, the input hardware may comprise CD-ROM drives or disk drives. In conjunction with a display terminal, a keyboard may also be used as an input device.
  • Output hardware may be coupled to the computer by output lines and may similarly be implemented by conventional devices.
  • the output hardware may include a display device for displaying a graphical representation of a binding pocket of this invention using a program such as QUANTA as described herein.
  • Output hardware might also include a printer, so that hard copy output may be produced, or a disk drive, to store system output for later use.
  • a CPU coordinates the use ofthe various input and output devices, coordinates data accesses from mass storage devices, accesses to and from working memory, and determines the sequence of data processing steps.
  • a number of programs may be used to process the machine-readable data of this invention. Such programs are discussed in reference to the computational methods ofdmg discovery as described herein. References to components ofthe hardware system are included as appropriate throughout the following description ofthe data storage medium.
  • Machine-readable storage devices useful in the present invention include, but are not limited to, magnetic devices, electrical devices, optical devices, and combinations thereof.
  • Examples of such data storage devices include, but are not limited to, hard disk devices, CD devices, digital video disk devices, floppy disk devices, removable hard disk devices, magneto-optic disk devices, magnetic tape devices, flash memory devices, bubble memory devices, holographic storage devices, and any other mass storage peripheral device.
  • these storage devices include necessary hardware (e.g., drives, controllers, power supplies, etc.) as well as any necessary media (e.g., disks, flash cards, etc.) to enable the storage of data.
  • the stmcture coordinates set forth in Figure 4 can be used to aid in obtaining stmctural information about another crystallized molecule or molecular complex.
  • the method ofthe invention allows determination of at least a portion ofthe three-dimensional stmcture of molecules or molecular complexes which contain one or more stmctural features that are similar to stmctural features of S. aureus MurB. These molecules are referred to herein as "structurally homologous" to S. aureus MurB.
  • Similar structural features can include, for example, regions of amino acid identity, conserved active site or binding site motifs, and similarly arranged secondary stmctural elements (e.g., ⁇ helices and ⁇ sheets).
  • stmctural homology is determined by aligning the residues ofthe two amino acid sequences to optimize the number of identical amino acids along the lengths of their sequences; gaps in either or both sequences are permitted in making the alignment in order to optimize the number of identical amino acids, although the amino acids in each sequence must nonetheless remain in their proper order.
  • two amino acid sequences are compared using the Blastp program, version 2.0.9, ofthe BLAST 2 search algorithm, as described by Tatiana et al., FEMS Microbiol Lett 174, 247-50 (1999), and available at http://www.ncbi.nlm.nih.gov/gorf/Dl2.html.
  • a structurally homologous molecule is a protein that has an amino acid sequence sharing at least 65% identity with a native or recombinant amino acid sequence of S. aureus MurB (for example, SEQ ID NO: 1). More preferably, a protein that is structurally homologous to S.
  • aureus MurB includes at least one contiguous stretch of at least 50 amino acids that shares at least 80% amino acid sequence identity with the analogous portion ofthe native or recombinant S. aureus MurB (for example, SEQ ID NO:l).
  • Methods for generating structural information about the structurally homologous molecule or molecular complex are well- known and include, for example, molecular replacement techniques.
  • this invention provides a method of utilizing molecular replacement to obtain stmctural information about a molecule or molecular complex whose structure is unknown comprising the steps of: (a) crystallizing the molecule or molecular complex of unknown structure; (b) generating an x-ray diffraction pattern from said crystallized molecule or molecular complex; and
  • Molecular replacement provides an accurate estimation ofthe phases for an unknown stmcture. Phases are a factor in equations used to solve crystal stmctures that cannot be determined directly. Obtaining accurate values for the phases, by methods other than molecular replacement, is a time- consuming process that involves iterative cycles of approximations and refinements and greatly hinders the solution of crystal stmctures. However, when the crystal stmcture of a protein containing at least a structurally homologous portion has been solved, the phases from the known stmcture provide a satisfactory estimate ofthe phases for the unknown structure.
  • this method involves generating a preliminary model of a molecule or molecular complex whose stmcture coordinates are unknown, by orienting and positioning the relevant portion of S. aureus MurB or the S. aureus MurB/ligand complex according to the stmcture coordinates listed in Figure 4 within the unit cell ofthe crystal ofthe unknown molecule or molecular complex so as best to account for the observed x-ray diffraction pattern ofthe crystal ofthe molecule or molecular complex whose stmcture is unknown. Phases can then be calculated from this model and combined with the observed x-ray diffraction pattern amplitudes to generate an electron density map ofthe stmcture whose coordinates are unknown.
  • a molecule that shares one or more stmctural features with S. aureus MurB as described above may also be sufficiently structurally homologous to S. aureus MurB to permit use ofthe stmcture coordinates of S. aureus MurB to solve its crystal stmcture.
  • the method of molecular replacement is utilized to obtain stmctural information about a molecule or molecular complex, wherein the molecule or molecular complex comprises at least one S. aureus MurB subunit or homolog.
  • a "subunit" of S. aureus MurB is an S. aureus MurB molecule that has been truncated at the N-terminus or the C- terminus, or both.
  • a "homolog" of S. aureus MurB is a protein that contains one or more amino acid substitutions, deletions, additions, or rearrangements with respect to the amino acid sequence of S.
  • structurally homologous molecules can contain deletions or additions of one or more contiguous or noncontiguous amino acids, such as a loop or a domain. Structurally homologous molecules also include "modified" S.
  • aureus MurB molecules that have been chemically or enzymatically derivatized at one or more constituent amino acid, including side chain modifications, backbone modifications, and N- and C- terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like.
  • a heavy atom derivative of S. aureus MurB is also included as an S. aureus MurB homolog.
  • the term "heavy atom derivative” refers to derivatives of S. aureus MurB produced by chemically modifying a crystal of S. aureus MurB.
  • a crystal is soaked in a solution containing heavy metal atom salts, or organometallic compounds, e.g., lead chloride, gold thiomalate, thiomersal or uranyl acetate, which can diffuse through the crystal and bind to the surface ofthe protein.
  • the location(s) ofthe bound heavy metal atom(s) can be determined by x-ray diffraction analysis ofthe soaked crystal. This information, in turn, is used to generate the phase information used to constmct three-dimensional stmcture ofthe protein (T.L. Blundell and N.L. Johnson, Protein Crystallography, Academic Press (1976)).
  • S. aureus MurB can crystallize in more than one crystal form
  • the structure coordinates of S. aureus MurB as provided by this invention are particularly useful in solving the stmcture of other crystal forms of S. aureus MurB or S. aureus MurB complexes.
  • the stmcture coordinates of S. aureus MurB as provided by this invention are particularly useful in solving the stmcture of S. aureus MurB mutants.
  • Mutants may be prepared, for example, by expression of S. aureus MurB cDNA previously altered in its coding sequence by oligonucleotide- directed mutagenesis. Mutants may also be generated by site-specific incorporation of unnatural amino acids into MurB proteins using the general biosynthetic method of C.J. Noren et al., Science. 244:182-188 (1989). In this method, the codon encoding the amino acid of interest in wild-type S.
  • aureus MurB is replaced by a "blank" nonsense codon, TAG, using oligonucleotide- directed mutagenesis.
  • a suppressor tRNA directed against this codon is then chemically aminoacylated in vitro with the desired unnatural amino acid.
  • the aminoacylated tRNA is then added to an in vitro translation system to yield a mutant S. aureus thymidylate kinase with the site-specific inco ⁇ orated unnatural amino acid.
  • Selenocysteine or selenomethionine may be inco ⁇ orated into wild-type or mutant S. aureus MurB by expression of S. aureus MurB-encoding cDNAs in auxotrophic E. coli strains (W.A.
  • the wild-type or mutagenized S. aureus MurB cDNA may be expressed in a host organism on a growth medium depleted of either natural cysteine or methionine (or both) but enriched in selenocysteine or selenomethionine (or both).
  • selenomethionine analogues may be prepared by down regulation methionine biosynthesis.
  • the stmcture coordinates of S. aureus MurB listed in Figure 4 are also particularly useful to solve the stmcture of crystals of S. aureus MurB, S. aureus MurB mutants or S. aureus MurB homologs co-complexed with a variety of chemical entities.
  • This approach enables the determination ofthe optimal sites for interaction between chemical entities, including candidate S. aureus MurB inhibitors and S. aureus MurB. Potential sites for modification within the various binding site ofthe molecule can also be identified. This information provides an additional tool for determining the most efficient binding interactions, for example, increased hydrophobic interactions, between S. aureus MurB and a chemical entity.
  • All ofthe complexes referred to above may be studied using well-known x-ray diffraction techniques and may be refined versus 1.5-3 A resolution x-ray data to an R value of about 0.20 or less using computer software, such as X-PLOR (Yale University, 81992, distributed by Molecular Simulations, Inc.; see, e.g., Blundell & Johnson, supra: Meth. Enzymol.. Vol. 114 & 115, H.W. Wyckoff et al., eds., Academic Press (1985)).
  • This information may thus be used to optimize known S. aureus MurB inhibitors, and more importantly, to design new S. aureus MurB inhibitors.
  • the invention also includes the unique three-dimensional configuration defined by a set of points defined by the stmcture coordinates for a molecule or molecular complex structurally homologous to S. aureus MurB as determined using the method ofthe present invention, structurally equivalent configurations, and magnetic storage media comprising such set of stmcture coordinates.
  • the invention includes structurally homologous molecules as identified using the method ofthe invention.
  • aureus MurB homolog Using homology modeling, a computer model of an S. aureus MurB homolog can be built or refined without crystallizing the homolog.
  • a preliminary model ofthe 5. aureus MurB homolog is created by sequence alignment with S. aureus MurB, secondary structure prediction, the screening of stmctural libraries, or any combination of those techniques. Computational software may be used to carry out the sequence alignments and the secondary structure predictions.
  • Stmctural incoherences e.g., stmctural fragments around insertions and deletions, can be modeled by screening a stmctural library for peptides ofthe desired length and with a suitable conformation.
  • a side chain rotamer library may be employed.
  • the final homology model can be used to solve the crystal stmcture ofthe homolog by molecular replacement, as described above.
  • the preliminary model is subjected to energy minimization to yield an energy minimized model.
  • the energy irunimized model may contain regions where stereochemistry restraints are violated, in which case such regions are remodeled to obtain a final homology model.
  • the homology model is positioned according to the results of molecular replacement, and subjected to further refinement comprising molecular dynamics calculations.
  • Computational techniques can be used to screen, identify, select and design chemical entities capable of associating with S. aureus MurB or structurally homologous molecules. Knowledge ofthe stmcture coordinates for S. aureus MurB permits the design and/or identification of synthetic compounds and/or other molecules which have a shape complementary to the conformation of an S. aureus MurB binding site.
  • computational techniques can be used to identify or design chemical entities, such as inhibitors, agonists and antagonists, that associate with an S. aureus MurB binding pocket or an S. aureus MurB-like binding pocket. Inhibitors may bind to or interfere with all or a portion ofthe active site of S.
  • aureus MurB can be competitive, non- competitive, or uncompetitive inhibitors. Once identified and screened for biological activity, these inhibitors/agonists/antagonists may be used therapeutically or prophylactically to block S. aureus MurB activity and, thus, inhibit the growth of the bacteria or cause its death. Stmcture-activity data for analogs of ligands that bind to or interfere with S. aureus MurB or S. aureus MurB-like binding pockets can also be obtained computationally.
  • chemical entity refers to chemical compounds, complexes of two or more chemical compounds, and fragments of such compounds or complexes. Chemical entities that are determined to associate with S. aureus MurB are potential drag candidates.
  • Data stored in a machine-readable storage medium that is capable of displaying a graphical three-dimensional representation ofthe structure of S. aureus MurB or a structurally homologous molecule, as identified herein, or portions thereof may thus be advantageously used for drug discovery.
  • the structure coordinates ofthe chemical entity are used to generate a three- dimensional image that can be computationally fit to the three-dimensional image of S. aureus MurB or a structurally homologous molecule.
  • the three- dimensional molecular structure encoded by the data in the data storage medium can then be computationally evaluated for its ability to associate with chemical entities.
  • the protein stmcture can also be visually inspected for potential association with chemical entities.
  • One embodiment of the method of drug design involves evaluating the potential association of a known chemical entity with S. aureus MurB or a structurally homologous molecule, particularly with an S. aureus MurB binding pocket (e.g., an FAD binding pocket, a substrate binding pocket, etc.) or S. aureus MurB-like binding pocket.
  • the method of drug design thus includes computationally evaluating the potential of a selected chemical entity to associate with any ofthe molecules or molecular complexes set forth above.
  • This method comprises the steps of: (a) employing computational means to perform a fitting operation between the selected chemical entity and a binding pocket, or a pocket nearby the substrate binding pocket, ofthe molecule or molecular complex; and (b) analyzing the results of said fitting operation to quantify the association between the chemical entity and the binding pocket.
  • the method of drug design involves computer-assisted design of chemical entities that associate with S. aureus MurB, its homologs, or portions thereof. Chemical entities can be designed in a step-wise fashion, one fragment at a time, or may be designed as a whole or "de novo.” To be a viable drug candidate, the chemical entity identified or designed according to the method must be capable of structurally associating with at least part of an S. aureus MurB or S.
  • aureus MurB-like binding pockets and must be able, sterically and energetically, to assume a conformation that allows it to associate with the S. aureus MurB or S. aureus MurB-like binding pocket.
  • Non-covalent molecular interactions important in this association include hydrogen bonding, van der Waals interactions, hydrophobic interactions, and electrostatic interactions.
  • Conformational considerations include the overall three-dimensional stmcture and orientation ofthe chemical entity in relation to the binding pocket, and the spacing between various functional groups of an entity that directly interact with the S. aureus MurB-like binding pocket or homologs thereof.
  • the potential binding of a chemical entity to an S. aureus MurB or S. aureus MurB-like binding pocket is analyzed using computer modeling techniques prior to the actual synthesis and testing ofthe chemical entity. If these computational experiments suggest insufficient interaction and association between it and the S. aureus MurB or S. aureus MurB-like binding pocket, testing ofthe entity is obviated. However, if computer modeling indicates a strong interaction, the molecule may then be synthesized and tested for its ability to bind to or interfere with an S. aureus MurB or S. aureus MurB- like binding pocket. Binding assays to determine if a compound actually binds to S. aureus MurB can also be performed and are well known in the art.
  • Binding assays may employ kinetic or the ⁇ nodynamic methodology using a wide variety of techniques including, but not limited to, microcalorimetry, circular dichroism, capillary zone electrophoresis, nuclear magnetic resonance spectroscopy, fluorescence spectroscopy, and combinations thereof.
  • MurB or S. aureus MurB-like binding pocket This process may begin by visual inspection of, for example, an S. aureus MurB or S. aureus MurB-like binding pocket on the computer screen based on the S. aureus MurB stmcture coordinates listed in Figure 4 or other coordinates which define a similar shape generated from the machine-readable storage medium. Selected fragments or chemical entities may then be positioned in a variety of orientations, or docked, within the binding pocket. Docking may be accomplished using software such as QUANTA and SYBYL, followed by energy minimization and molecular dynamics with standard molecular mechanics forcefields, such as CHARMM and AMBER.
  • Specialized computer programs may also assist in the process of selecting fragments or chemical entities. Examples include GRID (P.J. Goodford, J. Med. Chem. 28:849-857 (1985); available from Oxford University, Oxford, UK); MCSS (A. Miranker et al., Proteins: Struct. Funct. Gen.,11 :29-34 (1991); available from Molecular Simulations, San Diego, CA); AUTODOCK (D.S. Goodsell et al., Proteins: Stmct. Funct. Genet. 8:195-202 (1990); available from Scripps Research Institute, La Jolla, CA); and DOCK (I.D. Kuntz et al., J. Mol. Biol.
  • S. aureus MurB binding compounds may be designed "de novo" using either an empty binding site or optionally including some portion(s) of a known inhibitor(s).
  • LUDI H.-J. Bohm, J. Comp. Aid. Molec. Design. 6:61-78 (1992); available from Molecular Simulations Inc., San Diego, CA); LEGEND (Y. Nishibata et al., Tetrahedron. 47:8985 (1991); available from Molecular Simulations Inc., San Diego, CA); LEGEND (Y. Nishibata et al., Tetrahedron. 47:8985 (1991); available from Molecular
  • an effective S. aureus MurB or S. aureus MurB-like binding pocket inhibitor must preferably demonstrate a relatively small difference in energy between its bound and free states (i.e., a small deformation energy of binding).
  • the most efficient S. aureus MurB or S. aureus MurB-like binding pocket inhibitors should preferably be designed with a deformation energy of binding of not greater than about 10 kcal/mole; more preferably, not greater than 7 kcal mole. S. aureus MurB or S.
  • aureus MurB-like binding pocket inhibitors may interact with the binding pocket in more than one conformation that is similar in overall binding energy.
  • the deformation energy of binding is taken to be the difference between the energy ofthe free entity and the average energy ofthe conformations observed when the inhibitor binds to the protein.
  • An entity designed or selected as binding to or interfering with an S. aureus MurB or S. aureus MurB-like binding pocket may be further computationally optimized so that in its bound state it would preferably lack repulsive electrostatic interaction with the target enzyme and with the surrounding water molecules.
  • Such non-complementary electrostatic interactions include repulsive charge-charge, dipole-dipole, and charge-dipole interactions.
  • Another approach encompassed by this invention is the computational screening of small molecule databases for chemical entities or compounds that can bind in whole, or in part, to a S. aureus MurB or S. aureus MurB-like binding pocket.
  • the quality of fit of such entities to the binding site may be judged either by shape complementarity or by estimated interaction energy (E.C. Meng et al., J. Comp. Chem.. 13, pp. 505-524 (1992)).
  • This invention also enables the development of chemical entities that can isomerize to short-lived reaction intermediates in the chemical reaction of a substrate or other compound that interferes with or with S. aureus MurB. Time-dependent analysis of stmctural changes in S.
  • aureus MurB during its interaction with other molecules is carried out.
  • the reaction intermediates of S. aureus MurB can also be deduced from the reaction product in co-complex with S. aureus MurB.
  • Such information is useful to design improved analogs of known S. aureus MurB inhibitors or to design novel classes of inhibitors based on the reaction intermediates ofthe S. aureus MurB and inhibitor co-complex. This provides a novel route for designing S. aureus MurB inhibitors with both high specificity and stability.
  • Yet another approach to rational drug design involves probing the S. aureus MurB crystal ofthe invention with molecules comprising a variety of different functional groups to determine optimal sites for interaction between candidate S. aureus MurB inhibitors and the protein. For example, high resolution x-ray diffraction data collected from crystals soaked in or co- crystallized with other molecules allows the determination of where each type of solvent molecule sticks. Molecules that bind tightly to those sites can then be further modified and synthesized and tested for their MurB inhibitor activity (J. Travis, Science, 262:1374 (1993)).
  • iterative drug design is used to identify inhibitors of S. aureus MurB. Iterative drug design is a method for optimizing associations between a protein and a compound by determining and evaluating the three-dimensional stmctures of successive sets of protein/compound complexes. In iterative drug design, crystals of a series of protein/compound complexes are obtained and then the three-dimensional stmctures of each complex is solved. Such an approach provides insight into the association between the proteins and compounds of each complex.
  • a compound that is identified or designed as a result of any of these methods can be obtained (or synthesized) and tested for its biological activity, e.g., inhibition of MurB activity.
  • compositions of this invention comprise an inhibitor of S. aureus MurB activity identified according to the invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
  • pharmaceutically acceptable carrier refers to a carrier(s) that is “acceptable” in the sense of being compatible with the other ingredients of a composition and not deleterious to the recipient thereof.
  • the pH ofthe formulation is adjusted with pharmaceutically acceptable acids, bases, or buffers to enhance the stability ofthe formulated compound or its delivery form.
  • compositions ofthe invention can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir. Oral administration or administration by injection is preferred.
  • parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, infra-articular, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection or infusion techniques. Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 75 mg/kg body weight per day ofthe S.
  • aureus MurB inhibitory compounds described herein are useful for the prevention and treatment of S. aureus MurB mediated disease.
  • the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a typical preparation will contain from about 5% to about 95% active compound (w/w).
  • such preparations contain from about 20% to about 80% active compound.
  • MurB was expressed using UC 15169, E. coli construct K12S (F' lacP) (pQE-10 murB).
  • MurB cloned into pQE-10 (Qiagen) was obtained from Human Genome Sciences.
  • the plasmid was transformed into the E. coli K12S F' cell line which has an ampicillin resistance marker.
  • Stock supplies ofthe culture were maintained at -80°C in Luria Broth containing ampicillin at 100 ⁇ g/mL with 10% glycerol added as a cryopreservative agent.
  • Seed fermentations were prepared in 100 mL volumes of M9 medium contained in 500 mL wide mouth fermentation flasks.
  • the formulation of basal M9 utilized for these studies was Na 2 HPO 4 , 6 g; KH 2 PO , 3 g; NH_jCl, 1.0 g; and NaCl, 0.5 g per liter of deionized water.
  • the pH was adjusted to 7.4 with concentrated KOH.
  • the medium was sterilized by autoclaving for 30 minutes. Prior to inoculation, the following filter sterilized solutions were added per liter of basal medium: IM MgSO 4 , 1.0 mL; IM
  • CaCl 0.3 mL; trace metal salts solution, 0.3 mL and 20% glucose, 20 mL.
  • the trace metal salts solution contained per liter of deionized water: MgCl 2 " 6H O, 39.44 g; MnSO 4 'H 2 O, 5.58 g; FeSO 4 ' 7H 2 0, 1.11 g; Na 2 MoO 4 ⁇ 2H 2 O, 0.48 g; CaCl 2 , 0.33 g; NaCl, 0.12 g; and ascorbic acid, 1.0 g.
  • Filter sterilized ampicillin was added to the medium at a final concentration of 100 ⁇ g/mL.
  • a 0.1 mL aliquot of the stock culture was inoculated into the medium and allowed to grow at 37 °C for 18 -20 hours with a shaking rate of 200 ⁇ m.
  • the mature seed culture was harvested by centrifugation and then resuspended in an equal volume of M9 medium. The resuspended seed was used to inoculate expression fermentations at a rate of 3%.
  • selenomethionine MurB For expression of selenomethionine MurB, M9 media was again utilized in 100 mL volumes containing 100 ⁇ g/mL of ampicillin. Multiple flasks were employed to achieve the desired production volume. Since UC 15169 is not a methionine auxotroph, inco ⁇ oration of selenomethionine was accomplished through down-regulation of methionine biosynthesis just prior to induction of MurB expression with IPTG, isopropyl thio- ⁇ -D-galactosidase (G.D. Van Duyne et al., J. Mol. Biol. 229, 105-24 (1993); T.E. Benson et al., Nat. Struct. Biol. 2, 644-53 (1995)).
  • the culture was grown at 37°C with a shaking rate of 200 ⁇ m until an A ⁇ ooof ⁇ 0.6.
  • the following filter sterilized amino acids were added.
  • L-lysine, L-threonine, and L-phenylalanine were added to final concentrations of 100 ⁇ g/mL.
  • L-leucine, L-isoleucine, and L-valine were added to final concentrations of 50 ⁇ g/mL.
  • Filter sterilized L- selenomethionine was added simultaneously to a final concentration of 50 ⁇ g/mL. After 15 - 20 minutes, protein expression was induced by the addition of filter sterilized IPTG to a final concentration of 1 mM.
  • the column was then washed with 4 column volumes of equilibration buffer and 22 column volumes of wash buffer (50 mM Tris, pH 7.8, 500 mM NaCl, 10% glycerol, 50 mM imidazole, 5 mM 2- mercaptoethanol) at a flow rate of 108 mL/hr and eluted with 2.5 column volumes of elution buffer (50 mM Tris, pH 7.8, 500 mM NaCl, 10% glycerol, 300 mM imidazole, 5 mM 2-mercaptoethanol) at a flow rate of 60 mL/hr.
  • wash buffer 50 mM Tris, pH 7.8, 500 mM NaCl, 10% glycerol, 50 mM imidazole, 5 mM 2-mercaptoethanol
  • DTT was added to the eluted material to a final concentration of 10 mM and the treated material was dialyzed for 22 hours against two changes of nitrogen sparged dialysis buffer (50 mM Tris pH 7.8, 500 mM NaCl, 10% glycerol, and 10 mM DTT). After dialysis the sample was sterile filtered, fractionated, and stored at -80°C.
  • the protein concentration was 2.42 mg/mL as determined by amino acid analysis.
  • the prepared MurB protein had the correct N-terminal sequence for the first 20 residues.
  • the mass, as measured by electrospray mass spectrometry, was 36,220 Da, in excellent agreement with the theoretical mass of 36,207 Da, indicating full inco ⁇ oration ofthe five selenomethionines into the protein.
  • Amino acid analysis gave a correlation coefficient of 0.99 between the recovered and theoretical amino acid composition, indicative not only of high purity but also ofthe correct amino acid composition in the protein.
  • Protein samples were buffer exchanged into 20mM HEPES pH 7.5, 5mM 2-mercaptoethanol and concentrated to 20 mg/mL using an Ultrafree 0.5 centrifugal filters with a Biomax 10K membrane (Millipore, Bedford, MA).
  • Selenomethionine MurB crystals were grown in 3 ⁇ L + 3 ⁇ L sitting drops in
  • IMCA-CAT Argonne National Labs
  • Beamline 17-ID afforded the opportunity to solve the S. aureus MurB structure by multiple anomalous dispersion (MAD) phasing.
  • EXAFS analysis revealed a sha ⁇ selenium K edge for the selenomethionine MurB (data not shown).
  • a three wavelength experiment was carried out with a low energy wavelength (12,000 eV, 1.0332 A), a wavelength corresponding to the inflection point ofthe abso ⁇ tion edge (12,659.4 eV, 0.97939 A), and a wavelength collected at the peak ofthe abso ⁇ tion edge (12,660.8 eV, 0.97928 A).
  • Figure 5 was made with Molscript 2.1 (P. Kraulis, J. Appl. Crvst. 24, 946-50 (1991)) and Raster3D (E.A. Merritt & D.J. Bacon, Meth. Enzvmol. 277, 505-24 (1997)), and Figures 7 and 11 were made with Molscript 2.1 only.
  • SEQ ID NO:2 E. Coli MurB protein.
  • SEQ ID NO:4 Aquifex aeolicus MurB protein.
  • SEQ ID NO: 5 Bacillus subtilis MurB protein.
  • SEQ ID NO: 7 Chlamydia pneumoniae MurB protein.
  • SEQ ID NO: 8 Rickettsia prowazekii MurB protein.
  • SEQ ID NO: 9 Haemophilus influenzae MurB protein.
  • SEQ ID NO: 10 Salmonella typhimurium MurB protein.
  • SEQ ID NO: 11 Bordetella pertussis MurB protein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The substrate free form of Staphylococcus aureus UDP-N-acetylenolpyruvylglucosamine reductase S. ureus MurB has been crystallized, and the three dimensional x-ray crystal structure has been solved to 2.3 Å resolution. The x-ray crystal structure is useful for solving the structure of other molecules or molecular complexes, and designing inhibitors of S. aureus MurB.

Description

CRYSTALLIZATION AND STRUCTURE DETERMINATION OF
STAPHYLOCOCCUS A UREUS UDP-N-
ACETYLENOLPYRUVYLGLUCOSAMINE REDUCTASE
(S. aureus MurB)
This application claims the benefit of U.S. Provisional Application Serial No. 60/147,164 filed 4 August 1999, which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
This invention relates to the crystallization and structure determination of Staphylococcus aureus UDP-N-acetylenolpyravylglucosamine reductase (S. aureus MurB).
BACKGROUND OF THE INVENTION
Reports of an increase in antibiotic resistant bacteria have stimulated efforts to find new classes of therapeutic agents that will prevent society from entering a "post-antibiotic age." Historically, three important cellular functions have been the major targets of antibiotics - cell wall biosynthesis, DNA replication, and protein translation. The biosynthesis of the bacterial cell wall, in particular the peptidoglycan polymer, is a particularly attractive target since this flexible structure provides protection for the cell against osmotic lysis. To date, most of the therapeutic agents discovered that target cell wall biosynthesis inhibit the later stages of peptidoglycan biosynthesis at the point where interstrand cross linking occurs between the peptide chains. Recent efforts have been directed toward purifying and characterizing all the enzymes in the peptidoglycan biosynthetic pathway with an eye toward designing novel enzyme inhibitors of these essential targets.
Bacterial peptidoglycan is a polymer which includes a repeating disaccharide subunit of N-acetylglucosamine and N-acetylmuramic acid and an extended four to five residue amino acid chain. The first step toward creating this peptidoglycan polymer involves the formation of UDP-N-acetylmuramic acid from UDP-N-acetylglucosamine by the enzymes MurA and MurB. MurA catalyzes the first stage of this transformation by transferring the enolpyruvate moiety of phosphoenolpyruvate to the 3' hydroxyl of UDP-N-acetylglucosamine with the release of inorganic phosphate. The resulting product, enolpyruvyl- UDP-N-acetylglucosamine (EP-UDPGlcΝAc), undergoes a reduction catalyzed by the MurB enzyme by utilizing one equivalent of ΝADPH and a solvent derived proton. This two electron reduction creates the lactyl ether of UDP- N- acetylmuramic acid upon which a five residue peptide chain is built. Construction of this pentapeptide is catalyzed in a nonribosomal fashion by the enzymes MurC, MurD, MurE, and MurF (Figure 1) in both Gram negative bacteria such as Escherichia coli and Gram positive bacteria such as Staphylococcus aureus. The resulting UDP- N-acetylmuramyl pentapeptide is subsequently attached to an undecaprenyl lipid moiety by MraY and joined to another sugar, UDP-N-acetylglucosamine by MurG. In Staphylococci the next steps of peptidoglycan biosynthesis involve another family of enzymes, FemX, FemA, and FemB which create a pentaglycine strand in a stepwise fashion on the amino terminus of the lysine side chain. This extended Lys-Gly5 chain serves as the interstrand bridge between nearby peptide strands. Crosslinking between strands can then occur between the lysine-pentapeptide bridge and the carbonyl of the fourth residue (D-Ala) with release of the terminal D-Ala in a transpeptidation step catalyzed by penicillin binding proteins.
While several laboratories have characterized some of the peptidoglycan biosynthetic enzymes for E. coli, little biochemistry or structural biology has been carried out on these enzymes in a clinically relevant Gram positive organism. Interest in the molecular mechanisms of peptidoglycan biosynthesis in Gram positive organisms has increased in recent years as methicillin resistant S. aureus strains have surfaced that have acquired resistance to the antibiotic vancomycin. SUMMARY OF THE INVENTION
In one aspect, the present invention provides a method for crystallizing an S. aureus MurB molecule or molecular complex that includes preparing purified S. aureus MurB at a concentration of about 1 mg/ml to about 50 mg/ml and crystallizing S. aureus MurB from a solution comprising about 1 wt. % to about 50 wt. % PEG, 0 wt. % to about 40 wt. % DMSO, about 100 mM to about 1 M ammonium or lithium sulfate, about 0 mM to about 20 mM 2-mercaptoethanol, about 0.005 mM to about 40 mM EP-UDPGlcNAc substrate, and buffered to a pH of about 5 to about 8. In another aspect, the present invention provides crystalline forms of an S. aureus MurB molecule. In one embodiment, a crystal of an S. aureus MurB is provided having the trigonal space group symmetry 12^.
In another aspect, the present invention provides a scalable three dimensional configuration of points derived from structure coordinates of at least a portion of an S. aureus MurB molecule or molecular complex. In one embodiment, the scalable three dimensional set of points is derived from structure coordinates of at least the backbone atoms of the amino acids representing a FAD and or substrate binding pocket of an S. aureus MurB molecule or molecular complex. In another embodiment, the scalable three dimensional set of points is derived from structure coordinates of at least a portion of a molecule or a molecular complex that is structurally homologous to an S. aureus MurB molecule or molecular complex. On a molecular scale, the configuration of points derived from a homologous molecule or molecular complex have a root mean square deviation of less than about 1.0 A from the structure coordinates of the molecule or complex
In another aspect, the present invention provides a molecule or molecular complex that includes at least a portion of an S. aureus MurB FAD and/or substrate binding pocket. In one embodiment, the S. aureus MurB FAD binding pocket includes the amino acids listed in Table 1, preferably the amino acids listed in Table 2, and more preferably the amino acids listed in Table 3, the FAD binding pocket being defined by a set of points having a root mean square deviation of less than about 1.7 A, preferably less than about 1.0 A, from points representing the backbone atoms of the amino acids. In another embodiment, the S. aureus MurB substrate binding pocket includes the amino acids listed in Table 4, preferably the amino acids listed in Table 5, and more preferably the amino acids listed in Table 6, the substrate binding pocket being defined by a set of points having a root mean square deviation of less than about 1.0 A from points representing the backbone atoms of the amino acids.
TABLE 1
Residues near the FAD binding site in S. aureus MurB Identified residues 4A away from the FAD
TYR 42 LEU 98 TYR 149 VAL 199
TYR 77 SER 115 MET 150 ARG 225
LEU 78 ILE 140 ALA 152 GLN 229
GLY 79 PRO 141 GLY 153 LEU 231
ASN 80 GLY 142 ALA 154 SER 235
GLY 81 SER 143 ARG 188 GLY 237
SER 82 GLY 145 ILE 192 PHE 274
ASN 83 GLY 146 LEU 197 ARG 310
ILE 84 ALA 147 VAL 198
TABLE 2
Residues near the FAD binding site in S. aureus MurB Identified residues 7A away from FAD
THR 41 LEU 99 VAL 148 LEU 200
TYR 42 SER 115 TYR 149 GLU 201
THR 43 GLY 116 MET 150 ARG 225
THR 76 ALA 117 ASN 151 GLN 229
TYR 77 ILE 119 ALA 152 PRO 230
LEU 78 PHE 136 GLY 153 LEU 231
GLY 79 GLY 139 ALA 154 TYR 233
ASN 80 ILE 140 TYR 155 PRO 234
GLY 81 PRO 141 ARG 188 SER 235
SER 82 GLY 142 ILE 192 CYS 236
ASN 83 SER 143 GLN 193 GLY 237
ILE 84 ILE 144 HIS 196 SER 238
ILE 85 GLY 145 LEU 197 PHE 274
ILE 96 GLY 146 VAL 198 ARG 310
LEU 98 ALA 147 VAL 199 ILE 312 TABLE 3
Residues near the FAD binding site in S. aureus MurB
Identified residues lOA away
LEU 37 SER 100 TYR 155 ARG 225
TYR 40 LEU 101 GLY 156 GLU 226
THR 41 ALA 113 GLY 157 LYS 228
TYR 42 GLY 114 GLU 158 GLN 229
THR 43 SER 115 VAL 159 PRO 230
LYS 44 GLY 116 LYS 160 LEU 231
THR 45 ALA 117 ALA 166 GLU 232
TYR 52 ALA 118 LEU 167 TYR 233
PRO 55 ILE 119 CYS 168 PRO 234
VAL 61 ILE 120 VAL 169 SER 235
VAL 65 GLU 135 ASN 170 CYS 236
VAL 75 PHE 136 LEU 183 GLY 237
THR 76 ALA 137 ASP 186 SER 238
TYR 77 CYS 138 TYR 187 VAL 239
LEU 78 GLY 139 ARG 188 SER 268
GLY 79 ILE 140 ASN 189 LYS 270
ASN 80 PRO 141 SER 190 HIS 271
GLY 81 GLY 142 ILE 191 GLY 273
SER 82 SER 143 ILE 192 PHE 274
ASN 83 ILE 144 GLN 193 MET 275
ILE 84 GLY 145 LYS 194 VAL 276
ILE 85 GLY 146 GLU 195 ASN 277
ILE 86 ALA 147 HIS 196 TYR 286
ILE 91 VAL 148 LEU 197 GLU 308
ILE 94 TYR 149 VAL 198 VAL 309
VAL 95 MET 150 VAL 199 ARG 310
ILE 96 ASN 151 LEU 200 ILE 311
SER 97 ALA 152 GLU 201 ILE 312
LEU 98 GLY 153 ALA 202
LEU 99 ALA 154 LEU 221
TABLE 4
Residues near the EP-UDPGlcNAc binding site in S. aureus MurB Identified residues 4A away from EP-UDPGlcNAc
TYR 155 GLN 229 GLN 253 PHE 274
TYR 187 GLY 237 GLN 258 FAD 401
ARG 188 SER 238 HIS 271
ARG 225 LYS 250 ALA 272 TABLE 5
Residues near the EP-UDPGlcNAc binding site in S. aureus MurB Identified residues 7A away from EP-UDPGlcNAc
SER 82 ARG 188 ARG 242 SER 268
ASN 83 ARG 224 PHE 247 THR 269
GLY 139 ARG 225 ALA 248 LYS 270
ILE 140 LYS 228 GLY 249 HIS 271
PRO 141 GLN 229 LYS 250 ALA 272
MET 150 CYS 236 LEU 251 GLY 273
GLY 153 GLY 237 ILE 252 PHE 274
ALA 154 SER 238 GLN 253 GLU 308
TYR 155 VAL 239 ASP 254 FAD 401
GLY 156 PHE 240 GLN 258
TYR 187 GLN 241 VAL 267
TABLE 6
Residues near the EP-UDPGlcNAc binding site in S. aureus MurB Identified residues lOA away from EP-UDPGlcNAc
TYR 42 TYR 155 SER 238 GLN 258
THR 43 GLY 156 VAL 239 GLY 259
GLY 81 GLY 157 PHE 240 VAL 267
SER 82 GLU 158 GLN 241 SER 268
ASN 83 TYR 187 ARG 242 TMR 269
ILE 84 ARG 188 PRO 243 LYS 270
PHE 136 LEU 221 HIS 246 HIS 271
ALA 137 ARG 224 PHE 247 ALA 272
CYS 138 ARG 225 ALA 248 GLY 273
GLY 139 GLU 226 GLY 249 PHE 274
ILE 140 SER 227 LYS 250 MET 275
PRO 141 LYS 228 LEU 251 ASN 306
GLY 142 GLN 229 ILE 252 ARG 307
MET 150 PRO 230 GLN 253 GLU 308
ASN 151 LEU 231 ASP 254 VAL 309
ALA 152 SER 235 SER 255 FAD 401
GLY 153 CYS 236 ASN 256
ALA 154 GLY 237 LEU 257
In another aspect, the present invention provides molecules or molecular complexes that are structurally homologous to an S. aureus MurB molecule or molecular complex. In another aspect, the present invention provides a machine readable storage medium including the structure coordinates of all or a portion of an S. aureus MurB molecule, molecular complex, a structurally homologous molecule or complex, including structurally equivalent structures, as defined herein, particularly an FAD or substrate binding pocket thereof, or a similarly shaped homologous binding pocket. A storage medium encoded with these data is capable of displaying on a computer screen, or similar viewing device, a three-dimensional graphical representation of a molecule or molecular complex which comprises a binding pocket or a similarly shaped homologous binding pocket.
In another aspect, the present invention provides a method for identifying inhibitors, ligands, and the like of an S. aureus MurB molecule by providing the coordinates of a molecule of S. aureus MurB to a computerized modeling system; identifying chemical entities that are likely to bind to or interfere with the molecule (e.g., screening a small molecule library); and, optionally, procuring or synthesizing and assaying the compounds or analogues derived therefrom for bioactivity. In another aspect, the present invention provides methods for designing inhibitors, ligands, and the like by providing the coordinates of a molecule of S. aureus MurB to a computerized modeling system; designing a chemical entity that is likely to bind to or interfere with the molecule; and, optionally, synthesizing the chemical entity and assaying the chemical entity for bioactivity. In another aspect, the present invention provides inhibitors and ligands designed by the above method. In one embodiment, a composition is provided that includes an inhibitor or ligand designed or identified by the above method. In another embodiment, the composition is a pharmaceutical composition.
In another aspect, the present invention provides a method involving molecular replacement to obtain structural information about a molecule or molecular complex of unknown structure. The method includes crystallizing the molecule or molecular complex, generating an x-ray diffraction pattern from the crystallized molecule or molecular complex, and applying at least a portion of the structure coordinates set forth in Figure 4 to the x-ray diffraction pattern to generate a three-dimensional electron density map of at least a portion of the molecule or molecular complex.
In another aspect, the present invention provides a method for homology modeling an S. aureus MurB homolog.
DEFINITIONS
Two crystallographic data sets (with structure factors F) are considered isomorphous if, after scaling,
Figure imgf000010_0001
F Σ FI is less than about 35% for the reflections between 8 A and 4 A.
ABBREVIATIONS
The following abbreviations are used throughout this disclosure: UDP-N-acetylenolpymvylglucosamine reductase (MurB).
Uridine diphospho-N-acetylglucosamine (UDPGlcΝAc).
Uridine diphospho-N-acetylglucosamine enolpyruvate (EP-UDPGlcΝAc).
Uridine diphospho-N-acetylmuramic acid (UDPMurΝAc).
Reduced β-nicotinamide adenine dinucleotide phosphate (ΝADPH). Isopropylthio-β-D-galactoside (IPTG).
Dithiothreitol (DTT).
Flavin adenine dinucleotide (FAD).
Dimethyl sulfoxide (DMSO).
Multiple anomalous dispersion (MAD). The following amino acid abbreviations are used throughout this disclosure:
A = Ala = Alanine T = Thr = Threonine
V = Val = Valine C = Cys = Cysteine
L = Leu = Leucine Y = Tyr = Tyrosine
I = He = Isoleucine N = Asn = Asparagine
P = Pro = Proline Q = Gin = Glutamine
F = Phe = Phenylalanine D = Asp = Aspartic Acid
W = Trp = Tryptophan E = Glu = Glutamic Acid M = Met = Methionine K = Lys = Lysine
G = Gly = Glycine R = Arg = Arginine S = Ser = Serine H = His = Histidine
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 shows the pathway for the biosynthesis of the UDP-N- acetylmuramyl pentapeptide, detailing the first two steps catalyzed by the enzymes MurA and MurB.
Figure 2 shows an amino acid sequence alignment for recombinant S. aureus (SEQ ID ΝO:l, which includes the His6 region) and E. coli MurB. Dots in the sequences indicate gaps inserted in order to optimize the alignment. Identical residues are indicate by | and similar residues are indicated by . and : symbols. Sequence alignment was performed using the program GAP (GCG Version 9, Genetics Computational Group, Madison, WI). Residues corresponding to the FAD binding region (domains 1 and 2) are overlined and those corresponding to the substrate binding region (domain 3) are dash underlined. Structural features that are present in the E. coli but not the S. aureus protein are boxed and were omitted from superpositions. In regions where there are significant deletions in the S. aureus protein compared to the E. coli protein, no significance should be given to the placement of the connecting residues in the S. aureus sequence. Protein sequences not observed due to disordered electron density for the N and C termini of S. aureus MurB are underlined.
Figure 3 shows a) solvent flattened MAD electron density map at 2.3 A resolution for residues 110-115 with the final model and b) final 2F0-FC electron density map at 2.3 A for residues 110-115 with the final model.
Figure 4 lists the atomic structure coordinates for molecule S. aureus MurB as derived by x-ray diffraction from a crystal of that complex. The following abbreviations are used in Figure 4:
"Atom" refers to the element whose coordinates are measured. The second column defines the number of the atom in the structure. The letters in the third column define the element. The fourth and fifth columns define the amino acid and the number of the amino acid in the structure, respectively.
"X, Y, Z" crystallographically define the atomic position of the element measured.
"Occ" is an occupancy factor that refers to the fraction of the molecules in which each atom occupies the position specified by the coordinates. A value of "1" indicates that each atom has the same conformation, i.e., the same position, in all molecules of the crystal.
"B" is a thermal factor that measures movement of the atom around its atomic center.
Figure 5 shows ribbon diagrams of a) S. aureus MurB structure with bound FAD cofactor and b) E. coli MurB structure with bound FAD cofactor and ΕP-UDPGlcNAc substrate.
Figure 6 shows secondary structure diagram for a) S. aureus MurB and b) E. coli MurB. The domain assignments are indicated with a dotted line. Naming of the secondary structure was made to correspond to the previously published E. coli MurB structure. Where new elements of secondary structure are present in the S. aureus structure, naming includes an "A."
Figure 7 shows the superposition of S. aureus MurB (thick lines) and E. coli MurB (thin lines). Residues used for superpositions of the various domains are: a) All Cα atoms in common between the two structures, b) Cα atoms in domain 1 (lower right of molecule as shown in part a). The arrow points to the additional N-terminal α helix and β strand present in the S. aureus MurB structure, c) Cα atoms in domain 2 (upper center of molecule as shown in part a). The arrow points to the Tyr 190 loop in the E. coli MurB structure which is absent in the S. aureus MurB structure, d) Cα atoms in domain 3 (lower left of molecule as shown in part a). The arrow points to the single split βαββ fold in the E. coli MurB structure that is absent in the S. aureus MurB structure. Figure 8 shows a schematic view of side chain and main chain interactions between S. aureus MurB and the FAD cofactor. Residues for the S. aureus enzyme ("SA" prefix) are indicated adjacent to the amino acid along with the corresponding residues for the E. coli enzyme ("EC" prefix). Distances which would allow hydrogen bonds with the FAD are shown as dotted lines. Figure 9 shows proposed binding interactions of S. aureus
MurB with the EP-UDPGlcNAc substrate ("SA prefix and parentheses) based on the E. coli MurB structure. Residues involved in EP-UDPGlcNAc binding in E. coli MurB are also shown ("EC" prefix).
Figure 10 shows the sequence alignment of a representative sample of MurB sequences from Genbank: MURB HELPY (Helicobacter pylori), MURB_AQUAE (Aquifex aeolicus), MURB_BACSU (Bacillus subtilis), MURB_BORBU (Borrelia burgdorferϊ), MURB CHLPN (Chlamydia pneumoniae), MURB_RICPR (Rickettsia prowazekii), MURB_SAURE (Staphylococcus aureus), MURB_ECOLI (Escherichia coli), MURB_HAEIN (Haemophilus influenzae), MURB SALTY (Salmonella typhimurium), and
MURB BORDE (Bordetella pertussis). Asterisks indicate the proposed active site residues involved in catalysis. Several other MurB sequences were not included in this alignment including Treponema pallidum MurB (class II MurB) and Mycobacterium tuberculosis MurB (class I MurB) because of additional insertions or deletions in these protein sequences which complicated the multiple sequence alignment. Figure 11 shows Cα backbone traces from three MurB structures (superposition based on the flavin binding domains). The two E. coli MurB structures (substrate free E. coli MurB shown as dotted lines, EP-UDPGlcNAc bound MurB shown as thin lines) show that the substrate binding domain is actually closer to the flavin binding domain in the absence of substrate than when the substrate is bound. The S. aureus MurB structure reveals the greatest displacement of the substrate binding domain from the flavin domain of the three structures.
Figure 12 lists the structure factors and multiple anomalous dispersion phases for the crystal structure of S. aureus MurB. "INDE" refers to the indices h, k, and 1 (columns 2, 3, and 4 respectively) of the lattice planes. "FOBS" refers to the structure factor of the observed reflections. "SIGMA" is the standard deviation for the observations. "PHAS" refers to the phase used for the observations. "FOM" refers to the figure of merit.
DETAILED DESCRIPTION OF THE INVENTION
Crystalline Form(s) and Method of Making
Applicants have produced crystals comprising S. aureus MurB that are suitable for x-ray crystallographic analysis. The three-dimensional structure of S. aureus MurB was solved using high resolution x-ray crystallography. Preferably, the crystal has the cubic space group Yl\i. More preferably, the crystal comprises cubic shaped unit cells, each unit cell having the dimensions a = b = c = 178.9 ± 20 A with a = β = γ = 90°. The crystallized enzyme has one molecule in the asymmetric unit and includes a bound FAD cofactor.
Purified S. aureus MurB, preferably at a concentration of about 1 mg/ml to about 50 mg/ml, may be crystallized, for example, using the sitting or hanging drop procedure from a solution including about 1 wt. % to about 50 wt. % polyethylene glycol (PEG, preferably having a number average molecular weight between about 200 and about 20,000), 0 to about 40 wt. % DMSO, about 100 mM to about 1 M ammonium or lithium sulfate, about 0 mM to about 20 mM 2-mercaptoethanol, about 0.005 mM to about 40 mM EP-UDPGlcNAc substrate, and buffered to a pH of about 5 to about 8. Use of a buffer having a pKa of between about 4 and 9 is preferred. Variation in buffer and buffer pH as well as other additives such as PEG is apparent to those skilled in the art and may result in similar crystals.
Accordingly, one embodiment of the invention provides an S. aureus MurB or S. aureus MurB/ligand crystal.
The invention further includes an S. aureus MurB crystal or S. aureus MurB/ligand crystal that is isomorphous with an S. aureus MurB crystal characterized by a unit cell having the dimensions a = b = c = 178.9 ± 20 A with a = β = γ = 90°.
X-rav Crvstallographic Analysis
Crystals of S. aureus MurB in the cubic space group 12 Ϊ 3 with cell constants a=b=c=178.9 A, α=β=γ=90° diffracted to 2.3 A resolution. Initial attempts with molecular replacement using the E. coli MurB coordinates (T.E. Benson et al., Nat. Struct. Biol. 2, 644-53 (1995)) were unsuccessful despite the near 50% similarity with the S. aureus sequence (Figure 2). Therefore, an independent set of phases was derived using multiple anomalous dispersion (MAD) with selenomethionine incorporated protein. S. aureus selenomethionine MurB was prepared by inhibiting endogenous methionine biosynthesis while supplementing the expressing cells with selenomethionine (G.D. Van Duyne et al., J. Mol. Biol. 229, 105-24 (1993); T.E. Benson et al., Nat. Struct. Biol. 2, 644-53 (1995)). Methionine biosynthesis down regulation eliminates the need for transferring the protein expression vector into a met' strain. This technique reduces the time and effort required for producing selenomethionine incoφorated protein and results in near quantitative incorporation of selenomethionine into the overexpressed protein. Anomalous and dispersive difference Pattersons revealed the presence of four selenium sites. Solvent-flattened multiple anomalous dispersion phases to 2.3 A revealed an exceptionally clear electron density map with no significant breaks in the main chain. A portion of the electron density map is shown in Figure 3. The structure was refined to 2.3 A resolution with an R-factor of 20.3% and a Free R-factor of 22.3% as described in Tables 7and 8.
Table 7. Data collection and phasing statistics
λ 1.0332 A λ 0.97939 A λ 0.97928 A
(12,000 eV) (12,659.4 eV) (12,660.8 eV)
Resolution 2.3 A 2.3 A 2.3 A
No. observations 252,156 267,578 268,391
No. unique refl. 39,984 40,336 40,394
% completeness 94.4% 95.2% 95.3% -sym 7.5% 9.5% 9.4%
Rcuiiis acentrics — 0.77 0.83
Rcuiiis anomalous 0.99 0.84 0.84
Phasing power
Centrics ~ 0.87 0.69 acentrics ~ 0.77 0.83
Mean figure of merit (to 2.3 A resolution) before solvent flattening 0.464 after solvent flattening 0.605
Table 8. Refinement Statistics
R-factor Free R-factor No. of reflections
10-2.3 A F> 2σ 20.3% 22.3% 33,156
Bonds (A) Angles(°) r.m.s deviation from ideal geometry 0.008 1.37
Number of atoms Average B-factor
Protein 2345 28.4
Waters 213 36.6
FAD 53 23.6
Total 2611 29.0
Each of the constituent amino acids of S. aureus MurB is defined by a set of structure coordinates as set forth in Figure 4. The term "structure coordinates" refers to Cartesian coordinates derived from mathematical equations related to the patterns obtained on diffraction of a monochromatic beam of x-rays by the atoms (scattering centers) of an S. aureus MurB complex in crystal form. The diffraction data are used to calculate an electron density map of the repeating unit of the crystal. The electron density maps are then used to establish the positions of the individual atoms of the S. aureus MurB protein or protein/ligand complex.
Slight variations in structure coordinates can be generated by mathematically manipulating the S. aureus MurB or S. aureus MurB/ligand structure coordinates. For example, the structure coordinates set forth in Figure 4 could be manipulated by crystallographic permutations of the structure coordinates, fractionalization of the structure coordinates, integer additions or subtractions to sets of the structure coordinates, inversion of the structure coordinates or any combination of the above. Alternatively, modifications in the crystal structure due to mutations, additions, substitutions, and/or deletions of amino acids, or other changes in any of the components that make up the crystal, could also yield variations in structure coordinates. Such slight variations in the individual coordinates will have little effect on overall shape. If such variations are within an acceptable standard error as compared to the original coordinates, the resulting three-dimensional shape is considered to be structurally equivalent. Structural equivalence is described in more detail below.
It should be noted that slight variations in individual structure coordinates of the S. aureus MurB or S. aureus MurB/ligand complex, as defined above, would not be expected to significantly alter the nature of chemical entities such as ligands that could associate with the binding pockets. In this context, the phrase "associating with" refers to a condition of proximity between a chemical entity, or portions thereof, and an S. aureus thymidylate kinase molecule or portions thereof. The association may be non-covalent, wherein the juxtaposition is energetically favored by hydrogen bonding, van der Waals forces, or electrostatic interactions, or it may be covalent. Thus, for example, a ligand that bound to or interfered with the active site binding pocket of S. aureus MurB would also be expected to bind to or interfere with another binding pocket whose structure coordinates define a shape that falls within the acceptable error.
It will be readily apparent to those of skill in the art that the numbering of amino acids in other isoforms of S. aureus thymidylate kinase may be different than that of S. aureus thymidylate kinase expressed in E. coli.
Overview of the Structure
S. aureus MurB is composed of three domains (Figures 5 and 6). Domains 1 and 2 are responsible for binding of the flavin adenine dinucleotide (FAD) cofactor while domain 3 is responsible for substrate binding. The r.m.s. deviation for all Cα atoms in common between the E. coli and S. aureus structures (236 residues out of the 326 S. aureus residues) is 2.20 A (Figure 7a). Superpositions for each of the three domains in S. aureus compared to their respective domains in the E. coli enzyme resulted in slightly better superpositions for domains 2 and 3 (Figure 7b-d). Domain 1 (residues 14-98) of S. aureus MurB has a r.m.s. deviation of 2.20 A for the Cα atoms compared to E. coli MurB. The second domain of S. aureus MurB (residues 101-229) has a r.m.s. deviation of 1.80 A for the Cα atoms of the corresponding residues in E. coli MurB. The r.m.s. deviation for domain 3 of the S. aureus enzyme
(residues 230-316) is 1.05 A for the Cα atoms corresponding to the portion of this domain present in the E. coli structure.
While the overall fold of the S. aureus MurB enzyme is similar to that of E. coli MurB, several exceptions indicate that the S. aureus MurB structure represents a significant structural variation for the UDP-N- acetylenolpy vylglucosamine reductases. The first major difference is the additional 32 amino acids that are present at the Ν-terminus of S. aureus MurB which are not present in the E. coli enzyme. While only 18 of these amino acids are observed in the electron density map (the remaining 14 amino acids are disordered), these residues form an additional α helix (αA) and β strand (βA) at the beginning of the peptide chain. Similar secondary structure elements in S. aureus MurB have been given the corresponding names from E. coli MurB (T.Ε. Benson et al., Nat. Struct. Biol. 2, 644-53 (1995)) in order to facilitate the discussion and new elements of secondary structure have been assigned lettered names. The βA strand adds an antiparallel strand to the central parallel β barrel which forms the base of domain 1. This β barrel has an extremely hydrophobic core burying the side chains of residues Leu 37, Leu 78, He 84, He 86, He 91, Val 95, and He 312.
The second major structural difference in S. aureus MurB is the absence of the loop between βl3 and α3 (residues 183 to 203 of E. coli MurB). To compensate for the loss of this loop, an additional turn of helix is added to α3 in order to make the connection between βl3 and α3 in S. aureus MurB. This loop serves an important role in E. coli MurB by positioning Tyr 190 to interact directly with the α phosphate of the ΕP-UDPGlcNAc ligand and to close the active site upon substrate binding (T.Ε. Benson et al., Structure 4, 47- 54 (1996)). Observations of the S. aureus MurB structure do not reveal any direct substitutes for Tyr 190 suggesting that this specific mechanism for substrate binding observed in E. coli MurB is not utilized in the S. aureus enzyme. In the E. coli MurB structure, the α phosphate of the ΕP-UDPGlcNAc also interacts with the side chain of Lys 217. This residue is conserved in the S. aureus MurB structure as residue Lys 228. Therefore, one would expect that the absence of Tyr 190 would lead to an increased importance for Lys 228 in the formation of a productive enzyme-substrate complex in S. aureus MurB. The third major structural difference is the deletion of a portion of the substrate binding domain in the S. aureus MurB protein structure. One of the α+β motifs present in the E. coli structure, the single split βαββ fold (βl4, α4, βl5, βl6) is absent in the S. aureus MurB structure. This portion of the E. coli structure provides several van der Waals contacts with the ΕP-UDPGlcNAc ligand. In the absence of this portion of the substrate binding domain, the ligand binding surface on S. aureus MurB is notably more narrow. Several minor differences in the main chain between the two structures are also observed. First, in the E. coli MurB, two residues in β5 and β6 are not found in the S. aureus MurB structure resulting in two shorter β strands for the S. aureus enzyme. Second, the hydrogen bonding distances and geometries for residues 143-151 in S. aureus MurB are consistent with a secondary structure assignment of an α helix (αB) for these residues in the core of the protein. This same region in the E. coli structure (residues 113-121) shows secondary structure similar to an α helix with allowed phi and psi angles, but with poor hydrogen bonding distances and geometries; therefore, this region was not assigned as an α helix in the original E. coli MurB structure (T.Ε. Benson et al., Nat. Struct. Biol. 2, 644-53 (1995)). Third, a single residue deletion in the S. aureus structure occurs in the loop between β9 and βlO leading to a shorter connection between these two strands. Finally, the last beta strand (β21) and alpha helix (α7) in the E. coli MurB structure are not observed in the S. aureus MurB structure. The exact secondary structure of these residues is unknown since the last nine residues of the C terminus of S. aureus MurB are disordered in the electron density map. Flavin Cofactor Binding
The conserved protein fold of MurB in the S. aureus enzyme is particularly pronounced for the flavin binding portion of the molecule (domains 1 and 2 - Figures 7 b,c). Not only is the flavin binding fold conserved, but also the conformation of the flavin adenine dinucleotide ligand is nearly identical between the two structures (r.m.s. deviation for all of the cofactor atoms comparing the S. aureus FAD and the E. coli FAD is 0.30 A ). This FAD binding fold in both MurB structures is a member of a new superfamily of flavin adenine dinucleotide binding proteins (A.G. Murzin, Cur. Op. Struct. Biol. 6, 386-94 (1996)). The other members of this FAD binding protein family for which protein structures have been solved include p -cresol methylhydroxylase from Pseudomonas putida (F.S. Matthews et al., Biochemistry 30, 238-47 (1991)), vanillyl-alcohol oxidase from Penicllium simplicissimum (A. Mattevi et al., Structure 5, 907-20 (1997)), and CO dehydrogenase from Oligotropha carboxidovorans (H. Dobbek et al., Proc. Natl. Acad. Sci USA 96, 8884-89 (1999)).
The protein side chain and main chain interactions with the FAD cofactor found in the S. aureus enzyme are mostly similar to those interactions observed in E. coli MurB. The N5 and O4 of the isoalloxazine ring of the flavin adenine dinucleotide interact with the guanidinium moiety of Arg 225 in a manner similar to that observed for Arg 214 in the E. coli MurB structure (Fig. 8). The sequence and positional conservation of this arginine in the structure suggests that it plays a role in the binding of the flavin and stabilization of the reduced cofactor during catalysis. Two other interactions to the isoalloxazine ring (N3 and O2) are maintained by the main chain nitrogen and carbonyl oxygen of Gly 153. Interactions with the ribityl sugar moiety are also similar to those observed in the E. coli MurB. The carbonyl oxygen of Pro 141 and the hydroxyl group of Ser 82 make hydrogen bonds to the first hydroxyl group and the carbonyl of Gly 146 interacts with the third hydroxyl moiety. The extensive interactions between the protein and the diphosphoadenine portion of the molecule are also well conserved with the main chain atoms of residues 79-83 which include the Gly-X-Gly motif found in the Rossman fold and provide important stabilizing interactions with the two phosphates. Two serines (Ser 82 and Ser 143) again serve to make specific contacts with the β phosphate moiety, but using a geometry different from E. coli MurB. The placement of Ser 82 is conserved with respect to its counterpart in E. coli MurB (Ser 50), but Ser 143 is three residues away (one turn of α helix B) from the position corresponding to the E. coli MurB Ser 116. While this places the serine hydroxyl on the opposite site of the phosphate (when compared to the E. coli MurB), the hydrogen bonding interaction is maintained. Finally, two residues make contacts to the 3' hydroxyl of the ribityl sugar, Tyr 149 and Arg 310. The corresponding residues in E. coli MurB for Tyr 149 is He 149 which does not make any hydrogen bonds to the ribityl sugar, but does make hydrophobic interactions with this part of the flavin. The substitution of tyrosine in S. aureus MurB at this position allows for both hydrogen bonding and hydrophobic contacts.
Active Site Arrangement and Implications for Substrate Binding
The electron density map in the active site of S. aureus MurB reveals regions of disconnected electron density that did not clearly resemble the ΕP-UDPGlcNAc substrate despite the presence of the substrate in the crystallization conditions. Therefore, the exact location and interactions between S. aureus MurB and the ΕP-UDPGlcNAc and/or NADPH substrate in the active site cannot be determined at this time. Analysis of the packing in the crystal lattice reveals that a symmetry related molecule protrudes into the active site of S. aureus MurB in this crystal. Specifically, two strands of the major beta sheet (β5 and β6) are situated at the active site opening. Superimposing the E. cø/i'-ΕP-UDPGlcNAc bound structure on the S. aureus MurB structure indicates that these strands from the symmetry related molecule would interfere with the binding of the uridine portion of the substrate. Many attempts were made to obtain a ligand bound crystal form of S. aureus MurB, but no crystallization conditions were identified which would support both crystallization of the protein and binding of ΕP-UDPGlcNAc.
Although this crystal form of S. aureus MurB does not contain either of the MurB substrates EP-UDPGlcNAc or NADPH, comparison of the S. aureus and E. coli structures reveals strict conservation of the active site residues. The three catalytic active site residues in E. coli, Arg 159 and Glu 325 that would stabilize the C2 acicarbanionic species and Ser 229 that would provide a proton to quench the intermediate, are strictly conserved in the S. aureus active site - Ser 238, Arg 188, and Glu 308 (Figure 9) (T.E. Benson et al., Nat. Struct. Biol. 2, 644-53 (1995)). In addition, two residues that were shown to play a role in substrate binding in the E. coli enzyme are also strictly conserved in the active site of S. aureus MurB (Tyr 187 and Lys 288). Two other residues shown to be important for substrate binding - Asn 233 and Gin 288 - are replaced in the S. aureus structure by Arg 242 and His 271 respectively. The only critical substrate binding residue that is not found in the S. aureus structure is the E. coli Tyr 190 which is absent due to the deletion of the loop between βl3 and α3 in S. aureus protein as previously noted. The absence of this single residue does not appear to compromise the ability of the enzyme to bind substrate since all of the other hydrogen bond interactions observed in the E. coli MurB structure would be maintained.
A comparison of the two MurB structures reveals that the S. aureus MurB possesses the same general fold that was observed in the E. coli MurB structure - an α + β protein with three domains. Two of these domains create a binding site for the flavin adenine dinucleotide cofactor and the third domain participates in substrate binding. Based on the high similarity between the two protein sequences, a related fold was clearly expected. Yet it is not surprising that differences between the two structures are evident in the substrate binding regions of the enzymes, since the sequence alignment reveals regions of significant deletions. The most relevant deletions that occur in the S. aureus MurB structure involve portions of the enzyme that play an important part in the binding of EP-UDPGlcNAc in E. coli MurB. The loop between β 13 and α3 in E. coli MurB contains Tyr 190 which undergoes a dramatic motion upon substrate binding. The absence of this loop and its key residue in the S. aureus structure suggests that ligand binding in this bacterial species has adapted to compensate for the loss of Tyr 190. The Km for EP-UDPGlcNAc with S. aureus MurB is 15μM (S. Swaney, personal communication) which is of the same magnitude as the Km for EP-UDPGlcNAc with E. coli MurB. This kinetic parameter suggests that the loss of Tyr 190 has little impact on the enzyme's ability to bind substrate. It is also possible that charged residues from other parts ofthe molecule could play a role in ligand binding. Interestingly, the other significant deletion also involves a part ofthe enzyme involved in substrate binding - the single split βαββ fold (βl4, α4, βl5 and βl6 in E. coli MurB). This portion of protein structure has a less specific purpose in the mechanism of action of MurB, but does serve to provide a surface on which the uridine portion ofthe EP-UDPGlcNAc substrate rests.
Although the MurB crystals were grown in the presence ofthe substrate EP-UDPGlcNAc, no interpretable electron density for the substrate was observed. The failure to obtain a substrate complex could be either the result of weak substrate binding to the enzyme under the conditions necessary for crystallization or the result of crystallization conditions which select for a crystal form that excludes substrate. Monitoring ligand binding by UN-visible spectroscopy shows the expected red shift ofthe flavin absorption spectrum associated with EP-UDPGlcΝAc as observed with the E. coli MurB enzyme (T.E. Benson et al., Biochemistry 36, 796-805 (1997)) suggesting that the substrate should be bound to the oxidized form ofthe S. aureus MurB. When the initial crystals did not show the presence of substrate in the active site, higher concentrations of substrate were employed in an attempt to produce a substrate complex. Since the original crystallization buffer was at pH 6.5, crystals were also grown at pH 8.0 within the optimal pH range for the S. aureus MurB enzymatic activity. Unfortunately, neither of these changes resulted in formation of a substrate complex in the crystals that were obtained. These results strongly suggest that the crystal form which is favored during crystallization selects against preserving the S. aureus MurB-EP-UDPGlcΝAc complex. Placement ofthe EP-UDPGlcΝAc substrate can be inferred from the E. coli MurB-EP-UDPGlcΝAc structure. The active site for MurB is defined by residues which stabilize the intermediate produced when a hydride is transferred from NI to C3 ofthe enolpyruvyl group and facilitate the quenching of this intermediate. Based on S. aureus MurB structure, a mechanism was proposed for stabilization of this acicarbanionic species by charge neutralization and/or by protonation. As in the E. coli model, two residues, Arg 188 and Glu 308, exist which could serve this mechanistic purpose. Similarly, Ser 238 corresponds to E. coli MurB Ser 229 which is proposed to serve as a general acid catalyst in conjunction with an active site water (T.E. Benson et al., Biochemistry 36, 806-11 (1997)). The Ser 238 hydroxyl is 6.3A away from NI ofthe FAD cofactor in the S. aureus MurB structure. Since the corresponding serine hydroxyl is similarly positioned (6.1 A from NI ) in the E. coli MurB structure, it appears that S. aureus MurB is well-positioned for reduction ofthe enolpyruvyl group.
An analysis of available MurB sequences in Genbank provides increasing evidence that these three active site residues play critical roles in stabilization and reduction ofthe C2 acicarbanion intermediate during catalysis.
In the sequence alignment shown in Figure 10, the active site glutamate (Glu
308 in S. aureus MurB and Glu 325 in E. coli MurB) is strictly conserved. The active site arginine (Arg 188 in S. aureus MurB and Arg 159 in E. coli MurB) is conserved in all species with the exception of Borrelia burgdorfei MurB in which a conservative substitution to a lysine is made. The active site serine is equally well conserved across species with the only exception being the MurB sequence from Chlamydia pneumoniae where a conservative Cys substitution is present. This conservation of active site residues suggests that mechanistically the UDP-N-acetylenolpyruvylglucosamine reductases are equivalent with respect to the reduction ofthe enolpyruvyl group.
In contrast, these sequence alignments also suggest that there are at least two structural scaffolds for the MurB family. Comparison ofthe sequences from Genbank reveals that the S. aureus MurB is not the only MurB sequence in which the E. coli Tyr 190 loop and the single split βαββ fold from the substrate binding domain (βl4, α4, βl5 and βl6 in E. coli MurB) are absent (Figure 10). This striking similarity among sequences indicates that many of these MurBs from other species would adopt the S. aureus MurB type three- dimensional structure as opposed to the E. coli MurB type three-dimensional structure. Thus, the trend suggests that at least two distinct classes of MurB protein structures exist - that ofthe E. coli type (type I MurB) and that ofthe S. aureus type (type H MurB) - which distinguishes the construction ofthe substrate binding domain and the manner in which these enzymes bind their substrates.
This classification of two types of MurB consists not only of secondary structural elements that are present or absent, but also of how these structural elements define a mode of substrate binding. A comparison ofthe substrate domain positions between S. aureus MurB and the two forms of E. coli MurB (substrate free and ΕP-UDPGlcNAc bound forms) is shown in Figure 11. This superposition reveals that S. aureus MurB's substrate binding domain is notably more displaced from domains 1 and 2 in either ofthe substrate free or the ΕP-UDPGlcNAc bound forms of E. coli MurB. While interactions between crystallographically related molecules hold domain 3 in this open conformation, this displacement reveals the flexibility ofthe enzyme to achieve an open conformation ofthe S. aureus enzyme with ready access to the ligand binding site. The process of binding ligand in the S. aureus MurB most likely involves closing ofthe enzyme by direct movement of domain 3 towards the flavin binding domains. In contrast, E. coli MurB facilitates ligand binding by an indirect mechanism involving the movement of domain 3 away from the flavin binding domain leading to the disruption ofthe stacking interaction between Tyr 190 and Tyr 254. This motion allows Tyr 190 to adopt a new rotameric configuration which provides a hydrogen bond to the α phosphate and closes off the active site from the solvent.
Binding pockets/active sites/other structural features
Applicants' invention has provided, for the first time, information about the shape and structure ofthe cofactor and substrate binding pockets of S. aureus MurB. Binding pockets are of significant utility in fields such as drug discovery. The association of natural ligands or substrates with the binding pockets of their corresponding receptors or enzymes is the basis of many biological mechanisms of action. Similarly, many drugs exert their biological effects through association with the binding pockets of receptors and enzymes. Such associations may occur with all or any parts ofthe binding pocket. An understanding of such associations helps lead to the design of drugs having more favorable associations with their target, and thus improved biological effects. Therefore, this information is valuable in designing potential inhibitors of S. aureus MurB-like binding pockets, as discussed in more detail below. A "molecular complex" means a protein in covalent or non- covalent association with a chemical entity or compound. The term "binding pocket" or "active site" as used herein, refers to a region of a molecule or molecular complex, that, as a result of its shape, favorably associates with another chemical entity. Thus, a binding pocket may include or consist of features such as cavities, surfaces, or interfaces between domains. Chemical entities that may associate with a binding pocket include, but are not limited to, cofactors, substrates, inhibitors, agonists, antagonists, etc.
The FAD binding pocket of S. aureus MurB is located on the interface between domains 1 and 2, and preferably includes the amino acids listed in Table 1, more preferably the amino acids listed in Table 2, and most preferably the amino acids listed in Table 3, as represented by the structure coordinates listed in Figure 4. It will be readily apparent to those of skill in the art that the numbering of amino acids in other isoforms of S. aureus MurB may be different than that of recombinant S. aureus MurB expressed in E. coli. Alternatively, the FAD binding pocket of S. aureus MurB includes those amino acids whose backbone atoms are situated within about 4 A, more preferably within about 7 A, most preferably within about 10 A, of one or more constituent atoms of a bound FAD cofactor or analog, as determined from the structure coordinates listed in Figure 4. Alternatively, the FAD binding pocket comprises those amino acids whose backbone atoms are situated within a sphere centered on the coordinates representing the alpha carbon atom of residue Asn 80, the sphere having a radius of about 16 A, preferably about 20 A, and more preferably about 25 A. The substrate binding pocket of S. aureus MurB is located in domain 3, and preferably includes the amino acids listed in Table 4, more preferably the amino acids listed in Table 5, and most preferably the amino acids listed in Table 6, as represented by the stmcture coordinates listed in Figure 4. Alternatively, the substrate binding pocket of S. aureus MurB includes those amino acids whose backbone atoms are situated within about 4 A, more preferably within about 7 A, most preferably within about 10 A, of one or more constituent atoms of a bound substrate or inhibitor, as determined from the structure coordinates listed in Figure 4. Alternatively, the substrate binding pocket comprises those amino acids whose backbone atoms are situated within a sphere centered on the coordinates representing the alpha carbon atom of residue Ser 238, the sphere having a radius of about 12 A, preferably about 20 A, and more preferably about 25 A.
The amino acid constituents of an S. aureus MurB binding pocket as defined herein, as well as selected constituent atoms thereof, are positioned in three dimensions in accordance with the structure coordinates listed in Figure 4. In one aspect, the stmcture coordinates defining the binding pocket of S. aureus MurB include structure coordinates of all atoms in the constituent amino acids; in another aspect, the stmcture coordinates ofthe binding pocket include stmcture coordinates of just the backbone atoms ofthe constituent atoms.
The term "S. aureus MurB-like binding pocket" refers to a portion of a molecule or molecular complex whose shape is sufficiently similar to at least a portion of a cofactor or substrate binding pocket of S. aureus MurB as to be expected to bind a structurally related cofactor such as FAD or structurally related substrates such EP-UDPGlcNAc and/or NADPH. A structurally equivalent binding pocket is defined by a root mean square deviation from the stmcture coordinates ofthe backbone atoms ofthe amino acids that make up the binding pockets in S. aureus MurB (as set forth in Figure 4) of at most about 1.5 A. How this calculation is obtained is described below. Accordingly, the invention thus provides molecules or molecular complexes comprising an S. aureus MurB binding pocket or S. aureus MurB- like binding pocket, as defined by the sets of stmcture coordinates described above.
Three-Dimensional Configurations X-ray structure coordinates define a unique configuration of points in space. Those of skill in the art understand that a set of stmcture coordinates for protein or an protein/ligand complex, or a portion thereof, define a relative set of points that, in turn, define a configuration in three dimensions. A similar or identical configuration can be defined by an entirely different set of coordinates, provided the distances and angles between coordinates remain essentially the same. In addition, a scalable configuration of points can be defined by increasing or decreasing the distances between coordinates by a scalar factor while keeping the angles essentially the same.
The present invention thus includes the scalable three- dimensional configuration of points derived from the stmcture coordinates of at least a portion of an S. aureus MurB molecule or molecular complex, as listed in Figure 4, as well as structurally equivalent configurations, as described below. Preferably, the scalable three-dimensional configuration includes points derived from stmcture coordinates representing the locations of a plurality ofthe amino acids defining an S. aureus MurB binding pocket.
In one embodiment, the scalable three-dimensional configuration includes points derived from stmcture coordinates representing the locations of the backbone atoms of a plurality of amino acids defining the S. aureus MurB FAD binding pocket, preferably the amino acids listed is Table 1, more preferably the amino acids listed in Table 2, and most preferably the amino acids listed in Table 3; in another embodiment, the three-dimensional configuration includes points derived from stmcture coordinates representing the locations ofthe side chain and the backbone atoms (other than hydrogens) of a plurality ofthe amino acids defining the S. aureus MurB FAD binding pocket, preferably the amino acids listed is Table 1, more preferably the amino acids listed in Table 2, and most preferably the amino acids listed in Table 3. In another embodiment, the scalable three-dimensional configuration includes points derived from stmcture coordinates representing the locations ofthe backbone atoms of a plurality of amino acids defining the S. aureus MurB substrate binding pocket, preferably the amino acids listed is Table 4, more preferably the amino acids listed in Table 5, and most preferably the amino acids listed in Table 6; in another embodiment, the three-dimensional configuration includes points derived from stmcture coordinates representing the locations ofthe side chain and the backbone atoms (other than hydrogens) of a plurality ofthe amino acids defining the S. aureus MurB substrate binding pocket, preferably the amino acids listed is Table 4, more preferably the amino acids listed in Table 5, and most preferably the amino acids listed in Table 6.
Likewise, the invention also includes the scalable three- dimensional configuration of points derived from structure coordinates of molecules or molecular complexes that are structurally homologous to S. aureus MurB, as well as structurally equivalent configurations. Structurally homologous molecules or molecular complexes are defined below. Advantageously, structurally homologous molecules can be identified using the stmcture coordinates of S. aureus MurB (Figure 4) according to a method ofthe invention. The configurations of points in space derived from structure coordinates according to the invention can be visualized as, for example, a holographic image, a stereodiagram, a model or a computer-displayed image, and the invention thus includes such images, diagrams or models.
Structurally Equivalent Crystal Structures
Various computational analyses can be used to determine whether a molecule or the binding pocket portion thereof is "structurally equivalent," defined in terms of its three-dimensional stmcture, to all or part of S. aureus MurB or its binding pockets. Such analyses may be carried out in current software applications, such as the Molecular Similarity application of QUANTA (Molecular Simulations Inc., San Diego, CA) version 4.1, and as described in the accompanying User's Guide. The Molecular Similarity application permits comparisons between different stmctures, different conformations ofthe same stmcture, and different parts ofthe same stmcture. The procedure used in Molecular Similarity to compare stmctures is divided into four steps: (1) load the stmctures to be compared; (2) define the atom equivalences in these structures; (3) perform a fitting operation; and (4) analyze the results.
Each structure is identified by a name. One structure is identified as the target (i.e., the fixed structure); all remaining stmctures are working stmctures (i.e., moving structures). Since atom equivalency within QUANTA is defined by user input, for the purpose of this invention equivalent atoms are defined as protein backbone atoms (N, Cα, C, and O) for all conserved residues between the two stmctures being compared. A conserved residue is defined as a residue that is structurally or functionally equivalent. Only rigid fitting operations are considered. When a rigid fitting method is used, the working stmcture is translated and rotated to obtain an optimum fit with the target structure. The fitting operation uses an algorithm that computes the optimum translation and rotation to be applied to the moving stmcture, such that the root mean square difference ofthe fit over the specified pairs of equivalent atom is an absolute minimum. This number, given in angstroms, is reported by QUANTA.
For the purpose of this invention, any molecule or molecular complex or binding pocket thereof, or any portion thereof, that has a root mean square deviation of conserved residue backbone atoms (N, Cα, C, O) of less than about 1.5 A, when superimposed on the relevant backbone atoms described by the reference stmcture coordinates listed in Figure 4, is considered
"structurally equivalent" to the reference molecule. That is to say, the crystal structures of those portions ofthe two molecules are substantially identical, within acceptable error. Particularly preferred structurally equivalent molecules or molecular complexes are those that are defined by the entire set of structure coordinates listed in Figure 4, ± a root mean square deviation from the conserved backbone atoms of those amino acids of not more than 1.5 A. More preferably, the root mean square deviation is less than about 1.0 A. The term "root mean square deviation" means the square root ofthe arithmetic mean ofthe squares ofthe deviations. It is a way to express the deviation or variation from a trend or object. For purposes of this invention, the "root mean square deviation" defines the variation in the backbone of a protein from the backbone of S. aureus MurB or a binding pocket portion thereof, as defined by the stmcture coordinates of S. aureus MurB described herein.
Machine Readable Storage Media
Transformation ofthe stmcture coordinates for all or a portion of S. aureus MurB or the S. aureus MurB/ligand complex or one of its binding pockets, for structurally homologous molecules as defined below, or for the structural equivalents of any of these molecules or molecular complexes as defined above, into three-dimensional graphical representations ofthe molecule or complex can be conveniently achieved through the use of commercially- available software.
The invention thus further provides a machine-readable storage medium comprising a data storage material encoded with machine readable data which, when using a machine programmed with instructions for using said data, is capable of displaying a graphical three-dimensional representation of any of the molecule or molecular complexes of this invention that have been described above. In a preferred embodiment, the machine-readable data storage medium comprises a data storage material encoded with machine readable data which, when using a machine programmed with instructions for using said data, is capable of displaying a graphical three-dimensional representation of a molecule or molecular complex comprising all or any parts of an S. aureus MurB binding pocket or an S. aureus MurB-like binding pocket, as defined above. In another preferred embodiment, the machine-readable data storage medium is capable of displaying a graphical three-dimensional representation of a molecule or molecular complex defined by the structure coordinates of all ofthe amino acids listed in Figure A, ± a root mean square deviation from the backbone atoms of said amino acids of not more than 1.5 A. In an alternative embodiment, the machine-readable data storage medium comprises a data storage material encoded with a first set of machine readable data which comprises the Fourier transform ofthe stmcture coordinates set forth in Figure 4, and which, when using a machine programmed with instructions for using said data, can be combined with a second set of machine readable data comprising the x-ray diffraction pattern of a molecule or molecular complex to determine at least a portion ofthe structure coordinates corresponding to the second set of machine readable data.
For example, a system for reading a data storage medium may include a computer comprising a central processing unit ("CPU"), a working memory which may be, e.g., RAM (random access memory) or "core" memory, mass storage memory (such as one or more disk drives or CD-ROM drives), one or more display devices (e.g., cathode-ray tube ("CRT") displays, light emitting diode ("LED") displays, liquid crystal displays ("LCDs"), elecfroluminescent displays, vacuum fluorescent displays, field emission displays ("FEDs"), plasma displays, projection panels, etc.), one or more user input devices (e.g., keyboards, microphones, mice, touch screens, etc.), one or more input lines, and one or more output lines, all of which are interconnected by a conventional bidirectional system bus. The system may be a stand-alone computer, or may be networked (e.g., through local area networks, wide area networks, intranets, extranets, or the internet) to other systems (e.g., computers, hosts, servers, etc.). The system may also include additional computer controlled devices such as consumer electronics and appliances.
Input hardware may be coupled to the computer by input lines and may be implemented in a variety of ways. Machine-readable data of this invention may be inputted via the use of a modem or modems connected by a telephone line or dedicated data line. Alternatively or additionally, the input hardware may comprise CD-ROM drives or disk drives. In conjunction with a display terminal, a keyboard may also be used as an input device. Output hardware may be coupled to the computer by output lines and may similarly be implemented by conventional devices. By way of example, the output hardware may include a display device for displaying a graphical representation of a binding pocket of this invention using a program such as QUANTA as described herein. Output hardware might also include a printer, so that hard copy output may be produced, or a disk drive, to store system output for later use. In operation, a CPU coordinates the use ofthe various input and output devices, coordinates data accesses from mass storage devices, accesses to and from working memory, and determines the sequence of data processing steps. A number of programs may be used to process the machine-readable data of this invention. Such programs are discussed in reference to the computational methods ofdmg discovery as described herein. References to components ofthe hardware system are included as appropriate throughout the following description ofthe data storage medium.
Machine-readable storage devices useful in the present invention include, but are not limited to, magnetic devices, electrical devices, optical devices, and combinations thereof. Examples of such data storage devices include, but are not limited to, hard disk devices, CD devices, digital video disk devices, floppy disk devices, removable hard disk devices, magneto-optic disk devices, magnetic tape devices, flash memory devices, bubble memory devices, holographic storage devices, and any other mass storage peripheral device. It should be understood that these storage devices include necessary hardware (e.g., drives, controllers, power supplies, etc.) as well as any necessary media (e.g., disks, flash cards, etc.) to enable the storage of data.
Structurally Homologous Molecules. Molecular Complexes. And Crystal Structures
The stmcture coordinates set forth in Figure 4 can be used to aid in obtaining stmctural information about another crystallized molecule or molecular complex. The method ofthe invention allows determination of at least a portion ofthe three-dimensional stmcture of molecules or molecular complexes which contain one or more stmctural features that are similar to stmctural features of S. aureus MurB. These molecules are referred to herein as "structurally homologous" to S. aureus MurB. Similar structural features can include, for example, regions of amino acid identity, conserved active site or binding site motifs, and similarly arranged secondary stmctural elements (e.g., α helices and β sheets). Optionally, stmctural homology is determined by aligning the residues ofthe two amino acid sequences to optimize the number of identical amino acids along the lengths of their sequences; gaps in either or both sequences are permitted in making the alignment in order to optimize the number of identical amino acids, although the amino acids in each sequence must nonetheless remain in their proper order. Preferably, two amino acid sequences are compared using the Blastp program, version 2.0.9, ofthe BLAST 2 search algorithm, as described by Tatiana et al., FEMS Microbiol Lett 174, 247-50 (1999), and available at http://www.ncbi.nlm.nih.gov/gorf/Dl2.html. Preferably, the default values for all BLAST 2 search parameters are used, including matrix = BLOSUM62; open gap penalty = 11, extension gap penalty = 1, gap x_dropoff = 50, expect = 10, wordsize = 3, and filter on. In the comparison of two amino acid sequences using the BLAST search algorithm, stmctural similarity is referred to as "identity." Preferably, a structurally homologous molecule is a protein that has an amino acid sequence sharing at least 65% identity with a native or recombinant amino acid sequence of S. aureus MurB (for example, SEQ ID NO: 1). More preferably, a protein that is structurally homologous to S. aureus MurB includes at least one contiguous stretch of at least 50 amino acids that shares at least 80% amino acid sequence identity with the analogous portion ofthe native or recombinant S. aureus MurB (for example, SEQ ID NO:l). Methods for generating structural information about the structurally homologous molecule or molecular complex are well- known and include, for example, molecular replacement techniques.
Therefore, in another embodiment this invention provides a method of utilizing molecular replacement to obtain stmctural information about a molecule or molecular complex whose structure is unknown comprising the steps of: (a) crystallizing the molecule or molecular complex of unknown structure; (b) generating an x-ray diffraction pattern from said crystallized molecule or molecular complex; and
(c) applying at least a portion ofthe stmcture coordinates set forth in Figure 4 to the x-ray diffraction pattern to generate a three-dimensional electron density map ofthe molecule or molecular complex whose structure is unknown. By using molecular replacement, all or part ofthe stmcture coordinates of S. aureus MurB or the S. aureus MurB/ligand complex as provided by this invention (and set forth in Figure 4) can be used to determine the stmcture of a crystallized molecule or molecular complex whose stmcture is unknown more quickly and efficiently than attempting to determine such information ab initio.
Molecular replacement provides an accurate estimation ofthe phases for an unknown stmcture. Phases are a factor in equations used to solve crystal stmctures that cannot be determined directly. Obtaining accurate values for the phases, by methods other than molecular replacement, is a time- consuming process that involves iterative cycles of approximations and refinements and greatly hinders the solution of crystal stmctures. However, when the crystal stmcture of a protein containing at least a structurally homologous portion has been solved, the phases from the known stmcture provide a satisfactory estimate ofthe phases for the unknown structure.
Thus, this method involves generating a preliminary model of a molecule or molecular complex whose stmcture coordinates are unknown, by orienting and positioning the relevant portion of S. aureus MurB or the S. aureus MurB/ligand complex according to the stmcture coordinates listed in Figure 4 within the unit cell ofthe crystal ofthe unknown molecule or molecular complex so as best to account for the observed x-ray diffraction pattern ofthe crystal ofthe molecule or molecular complex whose stmcture is unknown. Phases can then be calculated from this model and combined with the observed x-ray diffraction pattern amplitudes to generate an electron density map ofthe stmcture whose coordinates are unknown. This, in turn, can be subjected to any well-known model building and structure refinement techniques to provide a final, accurate stmcture ofthe unknown crystallized molecule or molecular complex (E. Lattman, "Use ofthe Rotation and Translation Functions," in Meth. Enzymol.. 115, pp. 55-77 (1985); M.G. Rossman, ed., "The Molecular Replacement Method," Int. Sci. Rev. Ser.. No. 13, Gordon & Breach, New York (1972)). Structural information about a portion of any crystallized molecule or molecular complex that is sufficiently structurally homologous to a portion of S. aureus MurB can be resolved by this method. In addition to a molecule that shares one or more stmctural features with S. aureus MurB as described above, a molecule that has similar bioactivity, such as the same catalytic activity, substrate specificity or ligand binding activity as S. aureus MurB, may also be sufficiently structurally homologous to S. aureus MurB to permit use ofthe stmcture coordinates of S. aureus MurB to solve its crystal stmcture.
In a preferred embodiment, the method of molecular replacement is utilized to obtain stmctural information about a molecule or molecular complex, wherein the molecule or molecular complex comprises at least one S. aureus MurB subunit or homolog. A "subunit" of S. aureus MurB is an S. aureus MurB molecule that has been truncated at the N-terminus or the C- terminus, or both. In the context ofthe present invention, a "homolog" of S. aureus MurB is a protein that contains one or more amino acid substitutions, deletions, additions, or rearrangements with respect to the amino acid sequence of S. aureus MurB, but that, when folded into its native conformation, exhibits or is reasonably expected to exhibit at least a portion ofthe tertiary (three- dimensional) stmcture of S. aureus MurB. For example, structurally homologous molecules can contain deletions or additions of one or more contiguous or noncontiguous amino acids, such as a loop or a domain. Structurally homologous molecules also include "modified" S. aureus MurB molecules that have been chemically or enzymatically derivatized at one or more constituent amino acid, including side chain modifications, backbone modifications, and N- and C- terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like. A heavy atom derivative of S. aureus MurB is also included as an S. aureus MurB homolog. The term "heavy atom derivative" refers to derivatives of S. aureus MurB produced by chemically modifying a crystal of S. aureus MurB. In practice, a crystal is soaked in a solution containing heavy metal atom salts, or organometallic compounds, e.g., lead chloride, gold thiomalate, thiomersal or uranyl acetate, which can diffuse through the crystal and bind to the surface ofthe protein. The location(s) ofthe bound heavy metal atom(s) can be determined by x-ray diffraction analysis ofthe soaked crystal. This information, in turn, is used to generate the phase information used to constmct three-dimensional stmcture ofthe protein (T.L. Blundell and N.L. Johnson, Protein Crystallography, Academic Press (1976)).
Because it is expected that S. aureus MurB can crystallize in more than one crystal form, the structure coordinates of S. aureus MurB as provided by this invention are particularly useful in solving the stmcture of other crystal forms of S. aureus MurB or S. aureus MurB complexes.
The stmcture coordinates of S. aureus MurB as provided by this invention are particularly useful in solving the stmcture of S. aureus MurB mutants. Mutants may be prepared, for example, by expression of S. aureus MurB cDNA previously altered in its coding sequence by oligonucleotide- directed mutagenesis. Mutants may also be generated by site-specific incorporation of unnatural amino acids into MurB proteins using the general biosynthetic method of C.J. Noren et al., Science. 244:182-188 (1989). In this method, the codon encoding the amino acid of interest in wild-type S. aureus MurB is replaced by a "blank" nonsense codon, TAG, using oligonucleotide- directed mutagenesis. A suppressor tRNA directed against this codon is then chemically aminoacylated in vitro with the desired unnatural amino acid. The aminoacylated tRNA is then added to an in vitro translation system to yield a mutant S. aureus thymidylate kinase with the site-specific incoφorated unnatural amino acid. Selenocysteine or selenomethionine may be incoφorated into wild-type or mutant S. aureus MurB by expression of S. aureus MurB-encoding cDNAs in auxotrophic E. coli strains (W.A. Hendrickson et al., EMBO J.. 9(5):1665-1672 (1990)). In this method, the wild-type or mutagenized S. aureus MurB cDNA may be expressed in a host organism on a growth medium depleted of either natural cysteine or methionine (or both) but enriched in selenocysteine or selenomethionine (or both). Alternatively, selenomethionine analogues may be prepared by down regulation methionine biosynthesis. (T.E. Benson et al., Nat. Struct. Biol.. 2:644-53 (1995); G.D. Van Duyne et al., 1 Mol. Biol. 229:105-24 (1993)).
The stmcture coordinates of S. aureus MurB listed in Figure 4 are also particularly useful to solve the stmcture of crystals of S. aureus MurB, S. aureus MurB mutants or S. aureus MurB homologs co-complexed with a variety of chemical entities. This approach enables the determination ofthe optimal sites for interaction between chemical entities, including candidate S. aureus MurB inhibitors and S. aureus MurB. Potential sites for modification within the various binding site ofthe molecule can also be identified. This information provides an additional tool for determining the most efficient binding interactions, for example, increased hydrophobic interactions, between S. aureus MurB and a chemical entity. For example, high resolution x-ray diffraction data collected from crystals exposed to different types of solvent allows the determination of where each type of solvent molecule resides. Small molecules that bind tightly to those sites can then be designed and synthesized and tested for their S. aureus MurB inhibition activity.
All ofthe complexes referred to above may be studied using well-known x-ray diffraction techniques and may be refined versus 1.5-3 A resolution x-ray data to an R value of about 0.20 or less using computer software, such as X-PLOR (Yale University, 81992, distributed by Molecular Simulations, Inc.; see, e.g., Blundell & Johnson, supra: Meth. Enzymol.. Vol. 114 & 115, H.W. Wyckoff et al., eds., Academic Press (1985)). This information may thus be used to optimize known S. aureus MurB inhibitors, and more importantly, to design new S. aureus MurB inhibitors. The invention also includes the unique three-dimensional configuration defined by a set of points defined by the stmcture coordinates for a molecule or molecular complex structurally homologous to S. aureus MurB as determined using the method ofthe present invention, structurally equivalent configurations, and magnetic storage media comprising such set of stmcture coordinates.
Further, the invention includes structurally homologous molecules as identified using the method ofthe invention.
Homology Modeling
Using homology modeling, a computer model of an S. aureus MurB homolog can be built or refined without crystallizing the homolog. First, a preliminary model ofthe 5. aureus MurB homolog is created by sequence alignment with S. aureus MurB, secondary structure prediction, the screening of stmctural libraries, or any combination of those techniques. Computational software may be used to carry out the sequence alignments and the secondary structure predictions. Stmctural incoherences, e.g., stmctural fragments around insertions and deletions, can be modeled by screening a stmctural library for peptides ofthe desired length and with a suitable conformation. For prediction ofthe side chain conformation, a side chain rotamer library may be employed. Where the S. aureus MurB homolog has been crystallized, the final homology model can be used to solve the crystal stmcture ofthe homolog by molecular replacement, as described above. Next, the preliminary model is subjected to energy minimization to yield an energy minimized model. The energy irunimized model may contain regions where stereochemistry restraints are violated, in which case such regions are remodeled to obtain a final homology model. The homology model is positioned according to the results of molecular replacement, and subjected to further refinement comprising molecular dynamics calculations.
Rational Drug Design
Computational techniques can be used to screen, identify, select and design chemical entities capable of associating with S. aureus MurB or structurally homologous molecules. Knowledge ofthe stmcture coordinates for S. aureus MurB permits the design and/or identification of synthetic compounds and/or other molecules which have a shape complementary to the conformation of an S. aureus MurB binding site. In particular, computational techniques can be used to identify or design chemical entities, such as inhibitors, agonists and antagonists, that associate with an S. aureus MurB binding pocket or an S. aureus MurB-like binding pocket. Inhibitors may bind to or interfere with all or a portion ofthe active site of S. aureus MurB, and can be competitive, non- competitive, or uncompetitive inhibitors. Once identified and screened for biological activity, these inhibitors/agonists/antagonists may be used therapeutically or prophylactically to block S. aureus MurB activity and, thus, inhibit the growth of the bacteria or cause its death. Stmcture-activity data for analogs of ligands that bind to or interfere with S. aureus MurB or S. aureus MurB-like binding pockets can also be obtained computationally.
The term "chemical entity," as used herein, refers to chemical compounds, complexes of two or more chemical compounds, and fragments of such compounds or complexes. Chemical entities that are determined to associate with S. aureus MurB are potential drag candidates.
Data stored in a machine-readable storage medium that is capable of displaying a graphical three-dimensional representation ofthe structure of S. aureus MurB or a structurally homologous molecule, as identified herein, or portions thereof may thus be advantageously used for drug discovery. The structure coordinates ofthe chemical entity are used to generate a three- dimensional image that can be computationally fit to the three-dimensional image of S. aureus MurB or a structurally homologous molecule. The three- dimensional molecular structure encoded by the data in the data storage medium can then be computationally evaluated for its ability to associate with chemical entities. When the molecular stmctures encoded by the data is displayed in a graphical three-dimensional representation on a computer screen, the protein stmcture can also be visually inspected for potential association with chemical entities. One embodiment of the method of drug design involves evaluating the potential association of a known chemical entity with S. aureus MurB or a structurally homologous molecule, particularly with an S. aureus MurB binding pocket (e.g., an FAD binding pocket, a substrate binding pocket, etc.) or S. aureus MurB-like binding pocket. The method of drug design thus includes computationally evaluating the potential of a selected chemical entity to associate with any ofthe molecules or molecular complexes set forth above. This method comprises the steps of: (a) employing computational means to perform a fitting operation between the selected chemical entity and a binding pocket, or a pocket nearby the substrate binding pocket, ofthe molecule or molecular complex; and (b) analyzing the results of said fitting operation to quantify the association between the chemical entity and the binding pocket. In another embodiment, the method of drug design involves computer-assisted design of chemical entities that associate with S. aureus MurB, its homologs, or portions thereof. Chemical entities can be designed in a step-wise fashion, one fragment at a time, or may be designed as a whole or "de novo." To be a viable drug candidate, the chemical entity identified or designed according to the method must be capable of structurally associating with at least part of an S. aureus MurB or S. aureus MurB-like binding pockets, and must be able, sterically and energetically, to assume a conformation that allows it to associate with the S. aureus MurB or S. aureus MurB-like binding pocket. Non-covalent molecular interactions important in this association include hydrogen bonding, van der Waals interactions, hydrophobic interactions, and electrostatic interactions. Conformational considerations include the overall three-dimensional stmcture and orientation ofthe chemical entity in relation to the binding pocket, and the spacing between various functional groups of an entity that directly interact with the S. aureus MurB-like binding pocket or homologs thereof.
Optionally, the potential binding of a chemical entity to an S. aureus MurB or S. aureus MurB-like binding pocket is analyzed using computer modeling techniques prior to the actual synthesis and testing ofthe chemical entity. If these computational experiments suggest insufficient interaction and association between it and the S. aureus MurB or S. aureus MurB-like binding pocket, testing ofthe entity is obviated. However, if computer modeling indicates a strong interaction, the molecule may then be synthesized and tested for its ability to bind to or interfere with an S. aureus MurB or S. aureus MurB- like binding pocket. Binding assays to determine if a compound actually binds to S. aureus MurB can also be performed and are well known in the art. Binding assays may employ kinetic or theπnodynamic methodology using a wide variety of techniques including, but not limited to, microcalorimetry, circular dichroism, capillary zone electrophoresis, nuclear magnetic resonance spectroscopy, fluorescence spectroscopy, and combinations thereof.
One skilled in the art may use one of several methods to screen chemical entities or fragments for their ability to associate with an S. aureus
MurB or S. aureus MurB-like binding pocket. This process may begin by visual inspection of, for example, an S. aureus MurB or S. aureus MurB-like binding pocket on the computer screen based on the S. aureus MurB stmcture coordinates listed in Figure 4 or other coordinates which define a similar shape generated from the machine-readable storage medium. Selected fragments or chemical entities may then be positioned in a variety of orientations, or docked, within the binding pocket. Docking may be accomplished using software such as QUANTA and SYBYL, followed by energy minimization and molecular dynamics with standard molecular mechanics forcefields, such as CHARMM and AMBER.
Specialized computer programs may also assist in the process of selecting fragments or chemical entities. Examples include GRID (P.J. Goodford, J. Med. Chem. 28:849-857 (1985); available from Oxford University, Oxford, UK); MCSS (A. Miranker et al., Proteins: Struct. Funct. Gen.,11 :29-34 (1991); available from Molecular Simulations, San Diego, CA); AUTODOCK (D.S. Goodsell et al., Proteins: Stmct. Funct. Genet. 8:195-202 (1990); available from Scripps Research Institute, La Jolla, CA); and DOCK (I.D. Kuntz et al., J. Mol. Biol. 161:269-288 (1982); available from University of California, San Francisco, CA). Once suitable chemical entities or fragments have been selected, they can be assembled into a single compound or complex. Assembly may be preceded by visual inspection ofthe relationship ofthe fragments to each other on the three-dimensional image displayed on a computer screen in relation to the structure coordinates of S. aureus MurB. This would be followed by manual model building using software such as QUANTA or SYBYL (Tripos Associates, St. Louis, MO). Useful programs to aid one of skill in the art in connecting the individual chemical entities or fragments include, without limitation, CAVEAT (P.A. Bartlett et al., in Molecular Recognition in Chemical and Biological Problems." Special Publ., Royal Chem. Soc, 78:182-196 (1989); G. Lauri et al., J. Comput. Aided Mol. Des. 8:51-66 (1994); available from the University of California, Berkeley, CA); 3D database systems such as ISIS (available from MDL Information Systems, San Leandro, CA; reviewed in Y.C. Martin, J. Med. Chem. 35:2145-2154 (1992)); and HOOK (M.B. Eisen et al., Proteins: Struc. Funct.. Genet. 19:199-221 (1994); available from Molecular Simulations, San Diego, CA). S. aureus MurB binding compounds may be designed "de novo" using either an empty binding site or optionally including some portion(s) of a known inhibitor(s). There are many de novo ligand design methods including, without limitation, LUDI (H.-J. Bohm, J. Comp. Aid. Molec. Design. 6:61-78 (1992); available from Molecular Simulations Inc., San Diego, CA); LEGEND (Y. Nishibata et al., Tetrahedron. 47:8985 (1991); available from Molecular
Simulations Inc., San Diego, CA); LeapFrog (available from Tripos Associates, St. Louis, MO); and SPROUT (V. Gillet et al., J. Comput. Aided Mol. Design 7:127-153 (1993); available from the University of Leeds, UK).
Once a compound has been designed or selected by the above methods, the efficiency with which that entity may bind to or interfere with an S. aureus MurB or S. aureus MurB-like binding pocket may be tested and optimized by computational evaluation. For example, an effective S. aureus MurB or S. aureus MurB-like binding pocket inhibitor must preferably demonstrate a relatively small difference in energy between its bound and free states (i.e., a small deformation energy of binding). Thus, the most efficient S. aureus MurB or S. aureus MurB-like binding pocket inhibitors should preferably be designed with a deformation energy of binding of not greater than about 10 kcal/mole; more preferably, not greater than 7 kcal mole. S. aureus MurB or S. aureus MurB-like binding pocket inhibitors may interact with the binding pocket in more than one conformation that is similar in overall binding energy. In those cases, the deformation energy of binding is taken to be the difference between the energy ofthe free entity and the average energy ofthe conformations observed when the inhibitor binds to the protein.
An entity designed or selected as binding to or interfering with an S. aureus MurB or S. aureus MurB-like binding pocket may be further computationally optimized so that in its bound state it would preferably lack repulsive electrostatic interaction with the target enzyme and with the surrounding water molecules. Such non-complementary electrostatic interactions include repulsive charge-charge, dipole-dipole, and charge-dipole interactions.
Specific computer software is available in the art to evaluate compound deformation energy and electrostatic interactions. Examples of programs designed for such uses include: Gaussian 94, revision C (M.J. Frisch, Gaussian, Inc., Pittsburgh, PA 81995); AMBER, version 4.1 (P. A. Kollman, University of California at San Francisco, 81995); QUANTA/CHARMM (Molecular Simulations, Inc., San Diego, CA 81995); Insight H/Discover (Molecular Simulations, Inc., San Diego, CA 81995); DelPhi (Molecular
Simulations, Inc., San Diego, CA 81995); and AMSOL (Quantum Chemistry Program Exchange, Indiana University). These programs may be implemented, for instance, using a Silicon Graphics workstation such as an Indigo with "IMPACT" graphics. Other hardware systems and software packages will be known to those skilled in the art.
Another approach encompassed by this invention is the computational screening of small molecule databases for chemical entities or compounds that can bind in whole, or in part, to a S. aureus MurB or S. aureus MurB-like binding pocket. In this screening, the quality of fit of such entities to the binding site may be judged either by shape complementarity or by estimated interaction energy (E.C. Meng et al., J. Comp. Chem.. 13, pp. 505-524 (1992)). This invention also enables the development of chemical entities that can isomerize to short-lived reaction intermediates in the chemical reaction of a substrate or other compound that interferes with or with S. aureus MurB. Time-dependent analysis of stmctural changes in S. aureus MurB during its interaction with other molecules is carried out. The reaction intermediates of S. aureus MurB can also be deduced from the reaction product in co-complex with S. aureus MurB. Such information is useful to design improved analogs of known S. aureus MurB inhibitors or to design novel classes of inhibitors based on the reaction intermediates ofthe S. aureus MurB and inhibitor co-complex. This provides a novel route for designing S. aureus MurB inhibitors with both high specificity and stability.
Yet another approach to rational drug design involves probing the S. aureus MurB crystal ofthe invention with molecules comprising a variety of different functional groups to determine optimal sites for interaction between candidate S. aureus MurB inhibitors and the protein. For example, high resolution x-ray diffraction data collected from crystals soaked in or co- crystallized with other molecules allows the determination of where each type of solvent molecule sticks. Molecules that bind tightly to those sites can then be further modified and synthesized and tested for their MurB inhibitor activity (J. Travis, Science, 262:1374 (1993)).
In a related approach, iterative drug design is used to identify inhibitors of S. aureus MurB. Iterative drug design is a method for optimizing associations between a protein and a compound by determining and evaluating the three-dimensional stmctures of successive sets of protein/compound complexes. In iterative drug design, crystals of a series of protein/compound complexes are obtained and then the three-dimensional stmctures of each complex is solved. Such an approach provides insight into the association between the proteins and compounds of each complex. This is accomplished by selecting compounds with inhibitory activity, obtaining crystals of this new protein/compound complex, solving the three dimensional stmcture ofthe complex, and comparing the associations between the new protein/compound complex and previously solved protein/compound complexes. By observing how changes in the compound affected the protein/compound associations, these associations may be optimized.
A compound that is identified or designed as a result of any of these methods can be obtained (or synthesized) and tested for its biological activity, e.g., inhibition of MurB activity.
Pharmaceutical Compositions
Pharmaceutical compositions of this invention comprise an inhibitor of S. aureus MurB activity identified according to the invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The term "pharmaceutically acceptable carrier" refers to a carrier(s) that is "acceptable" in the sense of being compatible with the other ingredients of a composition and not deleterious to the recipient thereof. Optionally, the pH ofthe formulation is adjusted with pharmaceutically acceptable acids, bases, or buffers to enhance the stability ofthe formulated compound or its delivery form.
Methods of making and using such pharmaceutical compositions are also included in the invention. The pharmaceutical compositions ofthe invention can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir. Oral administration or administration by injection is preferred. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, infra-articular, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection or infusion techniques. Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 75 mg/kg body weight per day ofthe S. aureus MurB inhibitory compounds described herein are useful for the prevention and treatment of S. aureus MurB mediated disease. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Preferably, such preparations contain from about 20% to about 80% active compound. In order that this invention be more fully understood, the following examples are set forth. These examples are for the puφose of illustration only and are not to be construed as limiting the scope ofthe invention in any way.
EXAMPLES
Example 1: Analysis of the Structure of S. aureus MurB
Expression of MurB and Incorporation of Selenomethionine S. aureus MurB was expressed using UC 15169, E. coli construct K12S (F' lacP) (pQE-10 murB). Genes and polypeptides derived from S. aureus, including S. aureus and MurB, are published in EP 786519 A2 and WO 0012678, both assigned to Human Genome Sciences. MurB cloned into pQE-10 (Qiagen) was obtained from Human Genome Sciences. For expression, the plasmid was transformed into the E. coli K12S F' cell line which has an ampicillin resistance marker. Stock supplies ofthe culture were maintained at -80°C in Luria Broth containing ampicillin at 100 μg/mL with 10% glycerol added as a cryopreservative agent.
Seed fermentations were prepared in 100 mL volumes of M9 medium contained in 500 mL wide mouth fermentation flasks. The formulation of basal M9 utilized for these studies was Na2HPO4, 6 g; KH2PO , 3 g; NH_jCl, 1.0 g; and NaCl, 0.5 g per liter of deionized water. The pH was adjusted to 7.4 with concentrated KOH. The medium was sterilized by autoclaving for 30 minutes. Prior to inoculation, the following filter sterilized solutions were added per liter of basal medium: IM MgSO4, 1.0 mL; IM
CaCl , 0.3 mL; trace metal salts solution, 0.3 mL and 20% glucose, 20 mL. The trace metal salts solution contained per liter of deionized water: MgCl2 " 6H O, 39.44 g; MnSO4'H2O, 5.58 g; FeSO4' 7H20, 1.11 g; Na2MoO4 ■ 2H2O, 0.48 g; CaCl2, 0.33 g; NaCl, 0.12 g; and ascorbic acid, 1.0 g. Filter sterilized ampicillin was added to the medium at a final concentration of 100 μg/mL. A 0.1 mL aliquot of the stock culture was inoculated into the medium and allowed to grow at 37 °C for 18 -20 hours with a shaking rate of 200 φm. The mature seed culture was harvested by centrifugation and then resuspended in an equal volume of M9 medium. The resuspended seed was used to inoculate expression fermentations at a rate of 3%.
For expression of selenomethionine MurB, M9 media was again utilized in 100 mL volumes containing 100 μg/mL of ampicillin. Multiple flasks were employed to achieve the desired production volume. Since UC 15169 is not a methionine auxotroph, incoφoration of selenomethionine was accomplished through down-regulation of methionine biosynthesis just prior to induction of MurB expression with IPTG, isopropyl thio-β-D-galactosidase (G.D. Van Duyne et al., J. Mol. Biol. 229, 105-24 (1993); T.E. Benson et al., Nat. Struct. Biol. 2, 644-53 (1995)). The culture was grown at 37°C with a shaking rate of 200 φm until an Aδooof ~0.6. At this point, the following filter sterilized amino acids were added. L-lysine, L-threonine, and L-phenylalanine were added to final concentrations of 100 μg/mL. L-leucine, L-isoleucine, and L-valine were added to final concentrations of 50 μg/mL. Filter sterilized L- selenomethionine was added simultaneously to a final concentration of 50 μg/mL. After 15 - 20 minutes, protein expression was induced by the addition of filter sterilized IPTG to a final concentration of 1 mM. Growth ofthe culture was continued at 200 φm for an additional 4 hours until an A^ooof ~2.0. This coincided with maximum growth and maximum expression of MurB. Cells were then harvested by centrifugation and frozen at -80°C. Under these conditions, the average yield of cell paste was 4 - 4.5 g/L. Selenomethionyl MurB comprised roughly 2 - 5% ofthe total cell protein with > 75% expressed in the soluble form. Purification of Selenomethionine MurB
All operations were performed at 4°C and 2-mercaptoethanol and DTT were added to buffers immediately before use. Three hundred milliliters of equilibration buffer (50 mM Tris, pH 7.8, 500 mM NaCl, 10% glycerol, 25 mM imidazole, 5 mM 2-mercaptoethanol) containing 0.2 mg/mL DNAse I
(Boehringer Mannheim #104159) was added to 26 g of cell paste obtained from 6 L of fermentation broth and was resuspended by using a Tekmar Tissumizer set on a power setting of 60. The suspension was homogenized by passing it twice through a Rannie homogenizer at 10,000 PSI. The homogenate was centrifuged at 39,200 x g for 60 minutes in a JA20 rotor in a Beckman J2-21 centrifuge. The supernatant was filtered by using a Nalgene 0.2 μm CN filter unit and applied to a Qiagen NTA Superflow column charged with nickel (column volume of 7.9 mL). The column was then washed with 4 column volumes of equilibration buffer and 22 column volumes of wash buffer (50 mM Tris, pH 7.8, 500 mM NaCl, 10% glycerol, 50 mM imidazole, 5 mM 2- mercaptoethanol) at a flow rate of 108 mL/hr and eluted with 2.5 column volumes of elution buffer (50 mM Tris, pH 7.8, 500 mM NaCl, 10% glycerol, 300 mM imidazole, 5 mM 2-mercaptoethanol) at a flow rate of 60 mL/hr. DTT was added to the eluted material to a final concentration of 10 mM and the treated material was dialyzed for 22 hours against two changes of nitrogen sparged dialysis buffer (50 mM Tris pH 7.8, 500 mM NaCl, 10% glycerol, and 10 mM DTT). After dialysis the sample was sterile filtered, fractionated, and stored at -80°C.
The protein concentration was 2.42 mg/mL as determined by amino acid analysis. The prepared MurB protein had the correct N-terminal sequence for the first 20 residues. The mass, as measured by electrospray mass spectrometry, was 36,220 Da, in excellent agreement with the theoretical mass of 36,207 Da, indicating full incoφoration ofthe five selenomethionines into the protein. Amino acid analysis gave a correlation coefficient of 0.99 between the recovered and theoretical amino acid composition, indicative not only of high purity but also ofthe correct amino acid composition in the protein. Protein Crystallization
Protein samples were buffer exchanged into 20mM HEPES pH 7.5, 5mM 2-mercaptoethanol and concentrated to 20 mg/mL using an Ultrafree 0.5 centrifugal filters with a Biomax 10K membrane (Millipore, Bedford, MA). Selenomethionine MurB crystals were grown in 3μL + 3μL sitting drops in
9.75% PEG 8000, 0.1 M cacodylic acid pH 6.5, 0.55 M ammonium sulfate, 20% DMSO, 5mM 2-mercaptoethanol with lmM EP-UDPGlcNAc substrate. These conditions were originally identified by screening for crystallization conditions with the methionine incoφorated S. aureus MurB. The hexagonal shaped crystals grew over a period of two to three weeks. The mother liquor served as the cryoprotectant for freezing during data collection at 100 K in liquid nitrogen.
Data Collection and Structure Determination. Access to synchrotron radiation at the Advance Photon Source at
Argonne National Labs (IMCA-CAT, Beamline 17-ID) afforded the opportunity to solve the S. aureus MurB structure by multiple anomalous dispersion (MAD) phasing. EXAFS analysis revealed a shaφ selenium K edge for the selenomethionine MurB (data not shown). A three wavelength experiment was carried out with a low energy wavelength (12,000 eV, 1.0332 A), a wavelength corresponding to the inflection point ofthe absoφtion edge (12,659.4 eV, 0.97939 A), and a wavelength collected at the peak ofthe absoφtion edge (12,660.8 eV, 0.97928 A). All diffraction data were collected on a 2k by 2k Bruker CCD detector. Data sets at each wavelength were processed separately with the program SAINT (Siemens Analytical X-ray Systems, Madison, WI) while keeping the anomalous pairs separate (Table 7). The inflection point and peak data sets were scaled to the remote energy data set using SCALEIT in CCP4 (Collaborative Computational Project, N.4 Acta Crvst. D50, 760-63 (1994)) by treating the remote wavelength as native. Anomalous and dispersive difference Patterson maps showed strong signals for 4 ofthe 5 selenium atoms suggesting the N-terminal methionine was disordered. Locations ofthe selenium sites were deteπnined using the automated Patterson solution routine in SHELX (G.M. Sheldrick & R.O. Gould, Acta Crvst. B51, 423-31 (1995)). The location of each selenium site was confirmed by the ability of individual sites to generate phases which could identify the other sites in cross difference Fourier calculations. All heavy atom parameter refinement and phasing calculations were carried out with MLPHARE (Z. Otwinowski, in Isomoφhous Replacement and Anomalous Scattering 80-86 (W. Wolf et al., eds., SERC Daresbury Laboratory, Warrington) (1991); Collaborative Computational Project, N.4 Acta Crvst. D50, 760-63 (1994)) by treating the remote wavelength as native and the edge and peak wavelengths as derivatives (V. Ramakrishnan et al., Nature 362, 219-23 (1993)). The phases were subsequently subjected to solvent flattening using the program DM (K.D. Cowtan & P. Main, Acta Crvst. D49, 148-57 (1993); K.D. Cowtan & P. Main, Acta Crvst. D54, 487-93 (1998); Collaborative Computational Project, N.4 Acta Crvst. D50, 760-63 (1994)). Model building was performed using the program CHAIN (J.S.
Sack, J. Mol. Graph. 6, 224-25 (1988)). The E. coli MurB model was used as a template for model building in order to speed the placement ofthe main chain atoms. All refinement steps were carried out using XPLOR 3.8.5.1 and XPLOR 98.0 (A.T. Brunger, Methods. Mol. Biol. 56, 245-66 (1996)) against the 1.0332A (low energy) data set. Several rounds of torsional dynamics (L.M. Rice & A.T. Brunger, Proteins 19, 277-90 (1994)) and simulated annealing (A.T. Brunger, J. Mol. Biol. 203, 803-16 (1988)) with rebuilding after each round of refinement were carried out. In the later stages of refinement, a bulk solvent model was included in order to properly account for inclusion of lower resolution data (J.S. Jiang & A.T. Brunger, J. Mol. Biol. 243, 100-15 (1994)). Progress ofthe refinement was monitored by the Free R factor which was calculated for 10% ofthe reflections that were not included in refinement (A.T. Brunger, Nature 355, 472-75 (1992)). Analysis by PROCHECK showed good main chain geometry and side chain torsion angles (R.A. Laskowski et al., J. Appl. Crvst. 26, 283-91 (1993)). Figure 3 was made with Setor (S.V. Evans, Mol. Graph. 11, 134-38 (1993)). Figure 5 was made with Molscript 2.1 (P. Kraulis, J. Appl. Crvst. 24, 946-50 (1991)) and Raster3D (E.A. Merritt & D.J. Bacon, Meth. Enzvmol. 277, 505-24 (1997)), and Figures 7 and 11 were made with Molscript 2.1 only.
Sequence Listing Free Text SEQ ID NO :1 Recombinant S. aureus MurB protein including polyhistidine (His6) region.
SEQ ID NO:2 E. Coli MurB protein.
SEQ ID NO: 3 Helicobacter pylori MurB protein.
SEQ ID NO:4 Aquifex aeolicus MurB protein. SEQ ID NO: 5 Bacillus subtilis MurB protein.
SEQ ID NO:6 Borrelia burgdorferi MurB protein.
SEQ ID NO: 7 Chlamydia pneumoniae MurB protein.
SEQ ID NO: 8 Rickettsia prowazekii MurB protein.
SEQ ID NO: 9 Haemophilus influenzae MurB protein. SEQ ID NO: 10 Salmonella typhimurium MurB protein.
SEQ ID NO: 11 Bordetella pertussis MurB protein.

Claims

What is claimed is:
1. A molecule or molecular complex comprising at least a portion of an S. aureus MurB or MurB-like FAD binding pocket, wherein the FAD binding pocket comprises the amino acids listed in Table 1, the FAD binding pocket being defined by a set of points having a root mean square deviation of less than about 1.7 A from points representing the backbone atoms of said amino acids as represented by the structure coordinates listed in Figure 4.
2. The molecule or molecular complex of claim 1, wherein the FAD binding pocket comprises the amino acids listed in Table 2.
3. The molecule or molecular complex of claim 1, wherein the FAD binding pocket comprises the amino acids listed in Table 3.
4. A molecule or molecular complex comprising at least a portion of an S. aureus MurB or MurB-like substrate binding pocket, wherein the substrate binding pocket comprises amino acids listed in Table 4, the substrate binding pocket being defined by a set of points having a root mean square deviation of less than about 1.0 A from points representing the backbone atoms of said amino acids as represented by the stmcture coordinates listed in Figure 4.
5. The molecule or molecular complex of claim 4, wherein the substrate binding pocket comprises the amino acids listed in Table 5.
6. The molecule or molecular complex of claim 4, wherein the substrate binding pocket comprises the amino acids listed in Table 6.
7. A molecule or molecular complex that is structurally homologous to an S. aureus MurB molecule or molecular complex, wherein the S. aureus MurB molecule or molecular complex is represented by at least a portion ofthe structure coordinates listed in Figure 4.
8. A scalable three dimensional configuration of points, at least a portion of said points derived from stmcture coordinates of at least a portion of an 5. aureus MurB molecule or molecular complex listed in Figure 4 comprising at least one of a MurB or MurB-like FAD or substrate binding pocket.
9. A scalable three dimensional configuration of points, wherein substantially all of said points are derived from stmcture coordinates of an S. aureus MurB molecule or molecular complex listed in Figure 4.
10. The scalable three dimensional configuration of points of claim 8 wherein at least a portion ofthe points derived from the S. aureus MurB stmcture coordinates are derived from structure coordinates representing the locations of at least the backbone atoms of amino acids defining an S. aureus MurB FAD binding pocket, the FAD binding pocket comprising the amino acids listed in Table 1.
11. The scalable three dimensional configuration of points of claim 10 wherein the FAD binding pocket comprises the amino acids listed in Table 2.
12. The scalable three dimensional configuration of points of claim 10 wherein the FAD binding pocket comprises the amino acids listed in Table 3.
13. The scalable three dimensional configuration of points of claim 8 wherein at least a portion ofthe points derived from the S. aureus MurB stmcture coordinates are derived from stmcture coordinates representing the locations of at least the backbone atoms of amino acids defining an S. aureus MurB substrate binding pocket, the substrate binding pocket comprising the amino acids listed in Table 4.
14. The scalable three dimensional configuration of points of claim 13 wherein the substrate binding pocket comprises the amino acids listed in Table 5.
15. The scalable three dimensional configuration of points of claim 13 wherein the substrate binding pocket comprises the amino acids listed in Table 6.
16. The scalable three dimensional configuration of points of claim 8 displayed as a holographic image, a stereodiagram, a model or a computer-displayed image.
17. A scalable three dimensional configuration of points, at least a portion ofthe points derived from structure coordinates of at least a portion of a molecule or a molecular complex that is structurally homologous to an S. aureus MurB molecule or molecular complex and comprises at least one of an S. aureus MurB or MurB-like FAD or substrate binding pocket.
18. The scalable three-dimensional configuration of points of claim 17 displayed as a holographic image, a stereodiagram, a model or a computer-displayed image
19. A machine-readable data storage medium comprising a data storage material encoded with machine readable data which, when using a machine programmed with instructions for using said data, is capable of displaying a graphical three- dimensional representation of at least one molecule or molecular complex selected from the group consisting of:
(i) a molecule or molecular complex comprising at least a portion of an S. aureus MurB or MurB-like FAD binding pocket comprising the amino acids listed in Table 1, the FAD binding pocket defined by a set of points having a root mean square deviation of less than about 1.7 A from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Figure 4; and
(ii) a molecule or molecular complex comprising at least a portion of an S. aureus MurB or MurB-like substrate binding pocket comprising the amino acids listed in Table 4, the substrate binding pocket defined by a set of points having a root mean square deviation of less than about 1.0 A from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Figure 4; and
(iii) a molecule or molecular complex that is structurally homologous to an S. aureus MurB molecule or molecular complex, wherein the S. aureus MurB molecule or molecular complex is represented by at least a portion ofthe stmcture coordinates listed in Figure 4.
20. A machine-readable data storage medium comprising a data storage material encoded with a first set of machine readable data which, when combined with a second set of machine readable data, using a machine programmed with instructions for using said first set of data and said second set of data, can determine at least a portion ofthe stmcture coordinates corresponding to the second set of machine readable data, wherein said first set of data comprises a Fourier transform of at least a portion ofthe stmctural coordinates for S. aureus MurB listed in Figure 4; and said second set of data comprises an x-ray diffraction pattern of a molecule or molecular complex of unknown stmcture.
21. A method for obtaining stmctural information about a molecule or a molecular complex of unknown stmcture comprising: crystallizing the molecule or molecular complex; generating an x-ray diffraction pattern from the crystallized molecule or molecular complex; applying at least a portion ofthe stmcture coordinates set forth Figure 4 to the x-ray diffraction pattern to generate a three-dimensional electron density map of at least a portion ofthe molecule or molecular complex whose stmcture is unknown.
22. A method for homology modeling an S. aureus MurB homolog comprising: aligning the amino acid sequence of an S. aureus MurB homolog with an amino acid sequence of S. aureus MurB and incoφorating the sequence ofthe S. aureus MurB homolog into a model of S. aureus MurB derived from stmcture coordinates set forth in Figure 4 to yield a preliminary model ofthe S. aureus MurB homolog; subjecting the preliminary model to energy minimization to yield an energy minimized model; remodeling regions ofthe energy minimized model where stereochemistry restraints are violated to yield a final model ofthe S. aureus MurB homolog.
23. A computer-assisted method for identifying an inhibitor of S. aureus MurB activity comprising: supplying a computer modeling application with a set of stmcture coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of an S. aureus MurB or MurB-like FAD binding pocket, the FAD binding pocket comprising the amino acids listed in Table 1; supplying the computer modeling application with a set of stmcture coordinates of a chemical entity; and determining whether the chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus MurB activity.
24. A computer-assisted method for identifying an inhibitor of S. aureus MurB activity comprising: supplying a computer modeling application with a set of stmcture coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of an S. aureus MurB or MurB-like substrate binding pocket, the substrate binding pocket comprising the amino acids listed in Table 4; supplying the computer modeling application with a set of stmcture coordinates of a chemical entity; and deteπnining whether the chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus MurB activity.
25. The method of claim 23, wherein the FAD binding pocket comprises the amino acids listed in Table 1, the FAD binding pocket being defined by a set of points having a root mean square deviation of less than about 1.7 A from points representing the backbone atoms of said amino acids as represented by stmcture coordinates listed in Figure 4.
26. The method of claim 24, wherein the substrate binding pocket comprises the amino acids listed in Table 4, the substrate binding pocket being defined by a set of points having a root mean square deviation of less than about 1.0 A from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Figure 4.
27. The method of claim 23 or 24, wherein determining whether the chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex comprises performing a fitting operation between the chemical entity and a binding pocket ofthe molecule or molecular complex, followed by computationally analyzing the results ofthe fitting operation to quantify the association between, or the interference with, the chemical entity and the binding pocket.
28. The method of claim 23 or 24 further comprising screening a library of chemical entities.
29. A computer-assisted method for designing an inhibitor of S. aureus MurB activity comprising: supplying a computer modeling application with a set of stmcture coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of an S. aureus MurB or MurB-like FAD binding pocket, the FAD binding pocket comprising the amino acids listed in Table 1; supplying the computer modeling application with a set of structure coordinates for a chemical entity; evaluating the potential binding or interfering interactions between the chemical entity and the FAD binding pocket ofthe molecule or molecular complex; structurally modifying the chemical entity to yield a set of stmcture coordinates for a modified chemical entity; and determining whether the modified chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to the molecule or molecular complex is indicative of potential inhibition of S. aureus MurB activity.
30. A computer-assisted method for designing an inhibitor of S. aureus MurB activity comprising: supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of an S. aureus MurB or MurB-like substrate binding pocket, the substrate binding pocket comprising the amino acids listed in Table 4; supplying the computer modeling application with a set of stmcture coordinates for a chemical entity; evaluating the potential binding or interfering interactions between the chemical entity and the substrate binding pocket ofthe molecule or molecular complex; structurally modifying the chemical entity to yield a set of stmcture coordinates for a modified chemical entity; and determining whether the modified chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to the molecule or molecular complex is indicative of potential inhibition of S. aureus MurB activity.
31. The method of claim 29, wherein the FAD binding pocket comprises the amino acids listed in Table 1, the FAD binding pocket being defined by a set of points having a root mean square deviation of less than about 1.7 A from points representing the backbone atoms of said amino acids as represented by stmcture coordinates listed in Figure 4.
32. The method of claim 30, wherein the subsfrate binding pocket comprises the amino acids listed in Table 4, the substrate binding pocket being defined by a set of points having a root mean square deviation of less than about 1.0 A from points representing the backbone atoms of said amino acids as represented by structure coordinates listed in Figure 4.
33. The method of claim 29 or 30, wherein determining whether the modified chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex comprises performing a fitting operation between the chemical entity and a binding pocket ofthe molecule or molecular complex, followed by computationally analyzing the results ofthe fitting operation to quantify the association between or interference with the chemical entity and the binding pocket.
34. The method of claim 29 or 30, wherein the set of stmcture coordinates for the chemical entity is obtained from a chemical fragment library
35. A computer-assisted method for designing an inhibitor of S. aureus MurB activity de novo comprising: supplying a computer modeling application with a set of stmcture coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of an S. aureus MurB or MurB-like FAD binding pocket, wherein the FAD binding pocket comprises the amino acids listed in Table 1; computationally building a chemical entity represented by set of stmcture coordinates; and determining whether the chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus MurB activity.
36. A computer-assisted method for designing an inhibitor of S. aureus MurB activity de novo comprising: supplying a computer modeling application with a set of stmcture coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of an S. aureus MurB substrate binding pocket, wherein the substrate binding pocket comprises the amino acids listed in Table 4; computationally building a chemical entity represented by set of stmcture coordinates; and determining whether the chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus MurB activity.
37. The method of claim 35, wherein the FAD binding pocket comprises the amino acids listed in Table 1, the FAD binding pocket being defined by a set of points having a root mean square deviation of less than about 1.7 A from points representing the backbone atoms of said amino acids as represented by stmcture coordinates listed in Figure 4.
38. The method of claim 36, wherein the substrate binding pocket comprises the amino acids listed in Table 4, the subsfrate binding pocket being defined by a set of points having a root mean square deviation of less than about 1.0 A from points representing the backbone atoms of said amino acids as represented by stmcture coordinates listed in Figure 4.
39. The method of claim 35 or 36, wherein deteπnining whether the chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex comprises performing a fitting operation between the chemical entity and a binding pocket ofthe molecule or molecular complex, followed by computationally analyzing the results ofthe fitting operation to quantify the association between or interference with the chemical entity and the binding pocket.
40. The method of any of claims 23, 24, 29, 30, 35, or 36 further comprising supplying or synthesizing the potential inhibitor, then assaying the potential inhibitor to determine whether it inhibits S. aureus MurB activity.
41. A method for making an inhibitor of S. aureus MurB activity, the method comprising chemically or enzymatically synthesizing a chemical entity to yield an inhibitor of S. aureus MurB activity, the chemical entity having been identified during a computer-assisted process comprising supplying a computer modeling application with a set of stmcture coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of a S. aureus MurB or MurB-like FAD binding pocket or substrate binding pocket; supplying the computer modeling application with a set of stmcture coordinates of a chemical entity; and determining whether the chemical entity is expected to bind to or interfere with the molecule or molecular complex at a binding pocket, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus MurB activity.
42. A method for making an inhibitor of S. aureus MurB activity, the method comprising chemically or enzymatically synthesizing a chemical entity to yield an inhibitor of S. aureus MurB activity, the chemical entity having been designed during a computer-assisted process comprising supplying a computer modeling application with a set of stmcture coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of a S. aureus MurB or MurB-like FAD binding pocket or substrate binding pocket; supplying the computer modeling application with a set of structure coordinates for a chemical entity; evaluating the potential binding interactions between the chemical entity and a binding pocket ofthe molecule or molecular complex; structurally modifying the chemical entity to yield a set of stmcture coordinates for a modified chemical entity; and deteπnining whether the chemical entity is expected to bind to or interfere with the molecule or molecular complex at the binding pocket, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus MurB activity.
43. A method for making an inhibitor of S. aureus MurB activity, the method comprising chemically or enzymatically synthesizing a chemical entity to yield an inhibitor of S. aureus MurB activity, the chemical entity having been designed during a computer-assisted process comprising supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex comprising at least a portion of a S. aureus MurB or MurB-like FAD binding pocket or substrate binding pocket; computationally building a chemical entity represented by set of structure coordinates; and deteπnining whether the chemical entity is expected to bind to or interfere with the molecule or molecular complex at a binding pocket, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S. aureus MurB activity.
44. An inhibitor of S. aureus MurB activity identified, designed or made according to the method of any ofthe claims 23, 24, 29, 30, 35, 36, 41, 42, or 43.
45. A composition comprising an inhibitor of S. aureus MurB activity identified, designed or made according to the method of any of claims 23, 24, 29, 30, 35, 36, 41, 42, or 43.
46. A pharmaceutical composition comprising an inhibitor of S. aureus MurB activity identified or designed according to the method of any of claims 23, 24, 29, 30, 35, 36, 41, 42, or 43 or a salt thereof, and pharmaceutically acceptable carrier.
47. A method for crystallizing an S. aureus MurB molecule or molecular complex comprising: preparing purified S. aureus MurB at a concentration of about 1 mg/ml to about 50 mg/ml; and crystallizing S. aureus MurB from a solution comprising about 1 wt. % to about 50 wt. % PEG, 0 wt. % to about 40 wt. % DMSO, about 100 mM to about 1 M ammonium or lithium sulfate, about 0 mM to about 20 mM 2- mercaptoethanol, about 0.005 mM to about 40 mM EP-UDPGlcNAc, and buffered to a pH of about 5 to about 8.
48. A crystal of S. aureus MurB.
49. The crystal of claim 48 having the trigonal space group symmetry 12^.
50. The crystal of claim 48 comprising a unit cell having dimensions a = b = c = 178.9 ± 20 A, and α = β = γ = 90°.
51. The crystal of claim 48 comprising atoms arranged in a spatial relationship represented by the stmcture coordinates listed in Figure 4.
52. The crystal of claim 48 wherein MurB has amino acid sequence SEQ ID NO:l.
53. The crystal of claim 48 wherein MurB amino acid sequence SEQ ID NO:l, except that at least one methionine is replaced with selenometi ionine.
PCT/US2000/021432 1999-08-04 2000-08-04 CRYSTALLIZATION AND STRUCTURE DETERMINATION OF STAPHYLOCOCCUS AUREUS UDP-N-ACETYLENOLPYRUVYLGLUCOSAMINE REDUCTASE (S. AUREUS MurB) WO2001011054A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001515839A JP2003523175A (en) 1999-08-04 2000-08-04 Crystallization and structure determination of Staphylococcus aureus UDP-N-acetylenolpyruvyl glucosamine reductase (S. aureusMurB)
EP00952557A EP1200599A1 (en) 1999-08-04 2000-08-04 CRYSTALLIZATION AND STRUCTURE DETERMINATION OF STPHYLOCOCCUS AUREUS UDP-N-ACETYLENOLPYRUVYLGLUCOSAMINE REDUCTASE (S. AUREUS MurB)
AU65231/00A AU782516B2 (en) 1999-08-04 2000-08-04 Crystallization and structure determination of Staphylococcus aureus UDP-N-acetylenolpyruvylglucosamine reductase (S. aureus MurB)
CA002378032A CA2378032A1 (en) 1999-08-04 2000-08-04 Crystallization and structure determination of staphylococcus aureus udp-n-acetylenolpyruvylglucosamine reductase (s. aureus murb)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14716499P 1999-08-04 1999-08-04
US60/147,164 1999-08-04

Publications (2)

Publication Number Publication Date
WO2001011054A1 true WO2001011054A1 (en) 2001-02-15
WO2001011054A9 WO2001011054A9 (en) 2002-09-26

Family

ID=22520515

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/021432 WO2001011054A1 (en) 1999-08-04 2000-08-04 CRYSTALLIZATION AND STRUCTURE DETERMINATION OF STAPHYLOCOCCUS AUREUS UDP-N-ACETYLENOLPYRUVYLGLUCOSAMINE REDUCTASE (S. AUREUS MurB)

Country Status (6)

Country Link
US (2) US6356845B1 (en)
EP (1) EP1200599A1 (en)
JP (1) JP2003523175A (en)
AU (1) AU782516B2 (en)
CA (1) CA2378032A1 (en)
WO (1) WO2001011054A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007520997A (en) * 2003-01-21 2007-08-02 スミスクライン ビーチャム コーポレーション ErbB4 co-crystal
WO2015106067A3 (en) * 2014-01-10 2015-11-12 Lucigen Corporation Lucigen yellow (lucy), a yellow fluorescent protein

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1200599A1 (en) * 1999-08-04 2002-05-02 PHARMACIA & UPJOHN COMPANY CRYSTALLIZATION AND STRUCTURE DETERMINATION OF STPHYLOCOCCUS AUREUS UDP-N-ACETYLENOLPYRUVYLGLUCOSAMINE REDUCTASE (S. AUREUS MurB)
US6438204B1 (en) * 2000-05-08 2002-08-20 Accelrys Inc. Linear prediction of structure factors in x-ray crystallography
WO2003033531A1 (en) * 2001-10-15 2003-04-24 Smithkline Beecham Corporation S8 rRNA-BINDING PROTEIN FROM THE SMALL RIBOSOMAL SUBUNIT OF STAPHYLOCOCCUS AUREUS
WO2004011638A2 (en) * 2002-07-31 2004-02-05 Affinium Pharmaceuticals, Inc. Deoxyuridine 5' triphosphate nucleotidohydrolase polypeptides and structures
EP1613747A1 (en) * 2003-03-31 2006-01-11 Pfizer Products Inc. Crystal structure of 3 ,5 -cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
EP1627323A4 (en) * 2003-05-06 2008-04-09 New Century Pharmaceuticals Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on therir albumin binding properties
WO2005003765A1 (en) * 2003-06-30 2005-01-13 Astrazeneca Ab Isothermal titration calorimetry assays
CA2585115A1 (en) * 2003-11-03 2005-05-12 New Century Pharmaceuticals, Inc. Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties
BR112012011262A2 (en) * 2009-11-13 2019-09-24 Beckman Coulter Inc systems and methods for detecting the presence of a biological state using agglomeration

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0899335A2 (en) * 1997-08-25 1999-03-03 Smithkline Beecham Corporation MurB gene from Staphylococcus aureus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737248B2 (en) 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
WO2001016292A2 (en) 1999-09-01 2001-03-08 Human Genome Sciences, Inc. 37 staphylococcus aureus genes and polypeptides
US5865021A (en) * 1997-08-25 1999-02-02 Amsted Industries Incorporated Coated roller chain pin
US6521441B1 (en) 1998-03-20 2003-02-18 Human Genome Sciences, Inc. Staphylococcus aureus genes and polypeptides
EP1109911A4 (en) 1998-09-01 2005-04-27 Human Genome Sciences Inc Staphylococcus aureus genes and polypeptides
EP1200599A1 (en) * 1999-08-04 2002-05-02 PHARMACIA & UPJOHN COMPANY CRYSTALLIZATION AND STRUCTURE DETERMINATION OF STPHYLOCOCCUS AUREUS UDP-N-ACETYLENOLPYRUVYLGLUCOSAMINE REDUCTASE (S. AUREUS MurB)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0899335A2 (en) * 1997-08-25 1999-03-03 Smithkline Beecham Corporation MurB gene from Staphylococcus aureus

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ACTA CRYSTALLOGRAPHICA SECTION D BIOLOGICAL CRYSTALLOGRAPHY, vol. 52, no. 6, 1996, pages 1191 - 1193, ISSN: 0907-4449 *
BENSON TIMOTHY E ET AL: "Crystallization and preliminary X-ray crystallographic studies of UDP-N-acetylenolpyruvylglucosamine reductase.", PROTEIN SCIENCE, vol. 3, no. 7, 1994, pages 1125 - 1127, XP000960611, ISSN: 0961-8368 *
BENSON TIMOTHY E ET AL: "The structure of the substrate-free form of MurB, an essential enzyme for the synthesis of bacterial cell walls.", STRUCTURE (LONDON), vol. 4, no. 1, 1996, pages 47 - 54, XP000960650, ISSN: 0969-2126 *
CHAMBERLAIN DEAN ET AL: "Possible arrangement of the five domains in human complement factor I as determined by a combination of X-ray and neutron scattering and homology modeling.", BIOCHEMISTRY, vol. 37, no. 40, 6 October 1998 (1998-10-06), pages 13918 - 13929, XP002152650, ISSN: 0006-2960 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1992, RAY W J JR: "EFFECT OF POLYETHYLENE GLYCOL-400 AT LOW CONCENTRATIONS ON LONG-TERM GROWTH OF MUSCLE PHOSPHOGLUCOMUTASE CRYSTALS FROM CONCENTRATED SALT SOLUTIONS", XP002152653, Database accession no. PREV199294119155 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, ZHANG ERLI ET AL: "Crystallization and initial spectroscopic characterization of the heme-containing dehaloperoxidase from the marine polychaete Amphitrite ornata.", XP002152654, Database accession no. PREV199799333346 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 20 May 1999 (1999-05-20), KIYAMA RYUICHI ET AL: "Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.", XP002152652, Database accession no. PREV199900404023 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 30 March 1998 (1998-03-30), WIKOFF WILLIAM R ET AL: "Crystallization and preliminary X-ray analysis of the dsDNA bacteriophage HK97 mature empty capsid.", XP002152655, Database accession no. PREV199800210998 *
GSCHWEND D A ET AL: "MOLECULAR DOCKING TOWARDS DRUG DISCOVERY", JOURNAL OF MOLECULAR RECOGNITION,GB,HEYDEN & SON LTD., LONDON, vol. 9, 1996, pages 175 - 186, XP000882526, ISSN: 0952-3499 *
JOURNAL OF MEDICINAL CHEMISTRY, vol. 42, no. 10, 20 May 1999 (1999-05-20), pages 1723 - 1738, ISSN: 0022-2623 *
KUNTZ I D ET AL: "STRUCTURE-BASED MOLECULAR DESIGN", ACCOUNTS OF CHEMICAL RESEARCH,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 27, no. 5, May 1994 (1994-05-01), pages 117 - 123, XP000885741, ISSN: 0001-4842 *
PROTEINS STRUCTURE FUNCTION AND GENETICS, vol. 14, no. 2, 1992, pages 300 - 308, ISSN: 0887-3585 *
VIROLOGY, vol. 243, no. 1, 30 March 1998 (1998-03-30), pages 113 - 118, ISSN: 0042-6822 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007520997A (en) * 2003-01-21 2007-08-02 スミスクライン ビーチャム コーポレーション ErbB4 co-crystal
WO2015106067A3 (en) * 2014-01-10 2015-11-12 Lucigen Corporation Lucigen yellow (lucy), a yellow fluorescent protein
US9354175B2 (en) 2014-01-10 2016-05-31 Lucigen Corporation Lucigen yellow (LucY), a yellow fluorescent protein

Also Published As

Publication number Publication date
WO2001011054A9 (en) 2002-09-26
US20020156585A1 (en) 2002-10-24
CA2378032A1 (en) 2001-02-15
AU782516B2 (en) 2005-08-04
US6356845B1 (en) 2002-03-12
AU6523100A (en) 2001-03-05
EP1200599A1 (en) 2002-05-02
JP2003523175A (en) 2003-08-05

Similar Documents

Publication Publication Date Title
US20090062286A1 (en) Crystal Structure of SMYD3 Protein
US6197495B1 (en) Methods using the staphylococcus aureus glycyl tRNA synthetase crystalline structure
US6356845B1 (en) Crystallization and structure determination of Staphylococcus aureus UDP-N-acetylenolpyruvylglucosamine reductase (S. aureus MurB)
US6988041B2 (en) Crystallization and structure determination of Staphylococcus aureus NAD synthetase
WO2001010906A1 (en) Crystallization and structure determination of staphylococcus aureus elongation factor p
US20030129656A1 (en) Crystals and structures of a bacterial nucleic acid binding protein
AU781654B2 (en) Crystallization and structure determination of staphylococcus aureus thymidylate kinase
US6689595B1 (en) Crystallization and structure determination of Staphylococcus aureus thymidylate kinase
US20030166843A1 (en) Crystallization and structure determination of staphylococcus aureus thioredoxin reductase
EP1390488B1 (en) Crystal structure of 2c-methyl-d-erythritol 2,4-cyclodiphosphate synthase
US6864080B2 (en) Crystallization and structure of Staphylococcus aureus peptide deformylase
WO2004035730A2 (en) Crystals and structures of atp phosphoribosyltransferase
US20070020743A1 (en) Undecaprenyl pyrophosphate synthase (upps)enzyme and methods of use
US20020072105A1 (en) Crystallization and structure determination of FemA and FemA-like proteins
US20030171549A1 (en) Crystals and structures of YiiM proteins
US20050208639A1 (en) Crystal structure of staphylococcus undecaprenyl pyrophosphate synthase and uses thereof
US20040253178A1 (en) Crystals and structures of spleen tyrosine kinase SYKKD
US20030073219A1 (en) Crystal structure
US20040202644A1 (en) Crystallization and structure of Staphylococcus aureus peptide deformylase
WO2002002758A2 (en) Crystallization and structure of staphylococcus aureus peptide deformylase
WO2000058345A1 (en) NOVEL tRNA SYNTHETASE ENZYME, COMPOSITIONS CAPABLE OF BINDING TO SAID ENZYME, AND METHODS OF USE THEREOF
EP1476840A2 (en) Crystal structures of jnk-inhibitor complexes and binding pockets thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2378032

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 65231/00

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 515839

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000952557

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000952557

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/521-521/521, DRAWINGS, REPLACED BY NEW PAGES 1/624-624/624

WWG Wipo information: grant in national office

Ref document number: 65231/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000952557

Country of ref document: EP